VIENNA, AUSTRIA
Transcription
VIENNA, AUSTRIA
EADO FINAL PROGRAM 16th World Congress on Cancers of the Skin® 12th Congress of the European Association of Dermato-Oncology Or ga ed niz by H rt ube m Pe h a b e rg e r a n d Ch ris t o p h H o e l l e r AUGUST 31– SEPTEMBER 3, 2016 VI EN N A , AUST RI A .wc c www 6.c 1 0 s2 om Visit BMS at booth No22 to learn more The first and only approved I-O combination offering superior efficacy versus YERVOY1,2 OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults2 Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression2 I-O – Immuno-oncology References: 1. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and lpilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:23-34. 2. OPDIVO® Summary of Product Characteristics. Available at the booth. ABBREVIATED SMPC: ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 in the SmPC for how to report adverse reactions. NAME OF THE MEDICINAL PRODUCT: OPDIVO 10 mg/mL concentrate for solution for infusion. Pharmacotherapeutic Group: Antineoplastic agents, monoclonal antibodies. ATC code: L01XC17 QUALITATIVE AND QUANTITATIVE COMPOSITION: Each mL of concentrate contains 10 mg of nivolumab. One vial of 4 mL contains 40 mg of nivolumab. One vial of 10 mL contains 100 mg of nivolumab. Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology. List of excipients: Sodium citrate dihydrate, Sodium chloride, Mannitol (E421), Pentetic acid (diethylenetriaminepentaacetic acid), Polysorbate 80, Sodium hydroxide (for pH adjustment), Hydrochloric acid (for pH adjustment) Water for injections. THERAPEUTIC INDICATIONS: Melanoma: OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, 1506AT16PR06864-01 06/16 an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1 in the SmPC). Non-Small Cell Lung Cancer (NSCLC): OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 in the SmPC. MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom. CONTACT IN AUSTRIA: Bristol-Myers Squibb GesmbH, Vienna, Tel. +43 1 60143 -0 NR, prescription only. DATE OF LAST REVISION: May 2016 Further information, especially in regards to special warnings and precautions for use, Interactions with other medicinal products or other forms of interaction, pregnancy and lactation as well as undesirable effects are to be extracted from the published Summary of Product Characteristics (SmPC). © 2016 Bristol-Myers Squibb Company EADO Table of Contents Congress Information Societies and Contacts 2 Welcome Message 5 Acknowledgements 6 Information from A to Z 7 Public Transport Vienna 11 Hofburg Overview 12 Scientific Program Wednesday, August 31, 2016 14 Thursday, September 1, 2016 19 Friday, September 2, 2016 33 Saturday, September 3, 2016 49 List of Chairs and Invited Speakers 54 Poster Exhibition 56 Industrial Exhibition List of Exhibitors 85 Exhibition Floor Plan 84 FSA Disclosure Requirement 87 Session Types SY PL Symposium Plenary Lecture FC SAT Free Communication Industry Symposium OT Others Congress Information Societies and Contacts Societies CONGRESS INFORMATION EADO Euro p ean A s s o ciation of D er mato O nc olo g y European Association of Dermato Oncology (EADO)* President Garbe, Claus Vice-President Stratigos, Alexander Treasurer Hauschild, Axel General Secretary Peris, Ketty Secretary for Members Malvehy, Josep Secretary for European Integration Forsea, Anna-Maria Past President Grob, Jean-Jacques Past President Pehamberger, Hubert *According to the respective website 2 Board Members Alper, Sibel Arenberger, Peter Bataille, Véronique Bylaitė-Bučinskienė, Matilda Del Marmol, Véronique Dreno, Brigitte Dummer, Reinhard Forsea, Ana-Maria Garbe, Claus Grob, Jean-Jacques Harwood, Catherine Hauschild, Axel Hoeller, Christoph Kandolf-Sekulovic, Lidija Kaufmann, Roland Lebbé, Céleste Malvehy, Josep Moreno-Ramírez, David Olah, Judit Pehamberger, Hubert Pellacani, Giovanni Peris, Ketty Robert, Caroline Stockfleth, Eggert Stratigos, Alexander Vieira, Ricardo Weinlich, Georg Zalaudek, Iris Skin Cancer Foundation* President Robins, Perry Senior Vice Presidents Amonette, Rex A. Hale, Elizabeth K. Hanke, C. William Moy, Ronald L. Perez, Maritza I. Sarnoff, Deborah S. Vice Presidents Goldberg, Leonard H. Halpern, Allan C. Quintana, Adelle T. Weinkle, Susan H. General Counsel Weiner, Bennett Esq. Secretary Robins, Elizabeth Esq. Executive Director Latore, Dan Congress Information Societies and Contacts Christoph Hoeller, MD Professor of Dermatology Medical University Vienna Department of Dermatology Währinger Gürtel 18–20 Vienna, Austria E: christoph.hoeller@meduniwien.ac.at Legal Organizer (PCO) MCI Deutschland GmbH MCI | Berlin Office Markgrafenstrasse 56 10117 Berlin, Germany P: +49 (0)30 204590 F: +49 (0)30 2045950 E: wccs2016@mci-group.com Registration and Accommodation E: registration.berlin@mci-group.com Exhibition and Sponsoring E: wccs-sponsoring@mci-group.com © WienTourismus / Christian Stemper Congress Presidents Hubert Pehamberger, MD Professor of Dermatology Medical Director Rudolfinerhaus Medical University Vienna E: hubert.pehamberger@meduniwien.ac.at CONGRESS INFORMATION Contacts 3 MORE THAN MEETS THE EYE – TREATING ACTINIC KERATOSIS AND BEYOND Satellite symposium Thursday, 1st September, 09:00–10:00 Geheime Ratstube Hofburg Vienna, Austria Chair: Professor Claus Garbe | Germany Please join us as we explore the concept of field cancerisation and personalised field therapy for the treatment of actinic keratosis (AK), with our renowned expert faculty who will discuss the current unmet needs in AK and the risk factors that may be linked to the recurrence of this condition and its progression to squamous cell carcinoma AGENDA Time Session Speaker 09:00 Welcome and introduction Professor Claus Garbe (Chair) Germany 09:15 What lies beneath? Optimising diagnosis of field cancerisation AK and beyond: Tailored therapy Dr Iris Zalaudek Austria to optimise patient outcomes Professor Jean-Jacques Grob France 09:45 Panel discussion All 09:55 Closing remarks Professor Claus Garbe (Chair) Germany 09:30 Release date: August 2016 Congress Information Dear Colleagues, The “World Congress on Cancers of the Skin” and the “Congress of the European Association of Dermato-Oncology” (EADO) have become major interdisciplinary meetings for clinicians and basic scientists working in the challenging fields of Melanoma and Non-Melanoma Skin Cancer. Both meetings will be held together as a Joint Meeting covering the entire spectrum of cutaneous malignancies. It is our pleasure to host this unique Joint Meeting of the 16th World Congress on Cancers of the Skin and the 12th EADO conference in the historic Hofburg Conference Center in the heart of Vienna. We feel privileged and honored that many of the world’s leading investigators in the field will actively participate in this meeting. Clinicians and researchers will focus on the state of the art in prevention, recognition, and treatment of cutaneous neoplasms covering Melanoma and Non Melanoma Skin Cancer as well as Lymphomas and Rare Skin Tumors. As the organizers of this meeting we cordially invite you to share with us days of scientific communication in the beautiful city of Vienna. Hubert Pehamberger Christoph Hoeller 5 CONGRESS INFORMATION © WienTourismus/Christian Stemper Welcome Message Congress Information We are delighted to give special thanks to our main sponsors: CONGRESS INFORMATION Platinum Sponsors Gold Sponsors Silver Sponsor Bronze Sponsors BIOPHARMACEUTICALS, INC. Advancing a New Front in the War Against Cancer 6 Acknowledgements Abstracts Approved abstracts have been published online as a supplement to the August issue of “Melanoma Research”. You may access these abstracts free of charge until August 2017 by visiting:: journals.lww.com/ melanomaresearch/pages/default.aspx Act of God It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or incidents not caused by the organizer, which would prevent its scheduled opening or continuance, the congress may be partially postponed or terminated as a whole. In this case, participants are not entitled to reclaim refunds on no account. Participants are obliged to have civil liability insurance. Certificate of Attendance All registered participants will receive a certificate of attendance. You are able to print your certificate at the self-printing stations in the Hall on the ground floor. Opening Hours FRI, September 2 SAT, September 3 12:00 PM–06:30 PM 07:00 AM–01:00 PM Climate Vienna belongs to the humid continental climate. In August the weather is warm. Average temperatures are 20°C during the day. At night the temperatures can decrease to 11°C. Information from A to Z Congress Documents Registration fee for participants covers: admission to scientific sessions and satellite symposia, congress bag with congress documents, admission to the exhibition. CONGRESS INFORMATION Congress Information Congress Language The official language of the congress will be English. Simultaneous translation will not be provided. Congress Venue Hofburg Vienna Heldenplatz 1010 Vienna, Austria P: +43 1 5873666 F: +43 1 5356426 Currency The official currency in Austria is Euro (EUR). Electricity In Austria electricity is supplied at 220V, 50Hz. For some devices from abroad converters will be needed. Insurance The congress organizers do not accept any liability for damages and/or losses of any kind which may be incurred by the congress participants or by any persons accompanying them. Delegates participate in all events at their risk. Participants are advised to take out insurances against loss, accidents or damage that could occur during the Congress. Verbal agreements will not be binding unless 7 CONGRESS INFORMATION Congress Information Information from A to Z they are confirmed in writing. Sole place of jurisdiction is Vienna. Austrian law is applicable. as a result of the congress or during all events. Registration of a participant entails acceptance of these conditions. Gastronomy The catering stations for the coffee and lunch breaks are located in the Hofburg Lounge, in the Hofburg Galerie and in the Seitengalerie. Participants will be offered snacks and beverages. Catering is not included in the registration fee. Lost & Found A Lost & Found box will be placed at the registration desk. Helpful Phone Numbers Taxi Vienna: +43 66 44 60 43 89 Taxi 40100: +43 140 100 Fire Service: 122 Police:133 Internet Access Free wireless internet access is available in the venue. Therefore a password is required. Name: HofburgSecured Password: wccs2016 Please ensure the wireless connection on your device is configured and your device is correctly protected for wireless usage. No technical support will be provided. Liability Disclaimer The organizers cannot be held liable for any hindrance or disruption of congress proceedings arising from political, social or economic events or any other unforeseen incidents beyond their control. The organizers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to congress participants, either during or 8 Media Check The media check is located in the Orchestergang on the first floor. Speakers are requested to hand in their presentations at least 3 hours before their talk. Speakers having a presentation during the first time slot in the morning are asked to hand in their slides the day before. Please do not bring a laptop or other media device to the session room. Opening Hours WED, August 31 THU, September 1 FRI, September 2 SAT, September 3 12:00 PM–06:00 PM 07:00 AM–06:00 PM 07:00 AM–06:00 PM 07:00 AM–12:00 PM Name Badges The name badge will be the official meeting document and should be worn at all times in order to gain entry to the meeting rooms and the exhibition halls. Admission to the conference will not be allowed without badge identification. In case of lost or forgotten badges, an administration fee of €20 will be charged. Parking Facilities There are no parking slots available at the Congress Venue. Please use the parking garages nearby: Garage Robert Stolz-Platz (500 m)* Price: €3.80/1h (day price: €38) Garage am Museumsquartier (Museumsplatz, 500m)* Price: €4/1h (day price: €22) Parkgarage Rathauspark (Universitätsring, 500m)* Price: €4/1h (day price: €40) * Opening hours: 24h/7 days a week Photography, Audio, Video and Mobile Phone Policy Audio, photo and video recording by any device (e.g. cameras, laptops, PDAs, mobile phones, watches) is strictly prohibited during all oral and poster sessions, unless prior permission is obtained from the congress organizer. Use of mobile phones is strictly prohibited during scientific sessions. Mobile phones must be switched off while attending sessions. Program Changes The organizer reserves the right to make changes if necessary. No full or partial refunds are made to the attendees in the event of cancellations or other changes in the program. Please note that changes will be posted at the registration desk and at the entrance of the session halls. Participants will be informed about the changes. Public Transportation Vienna offers an efficient and modern system of public transportation (called VOR), including underground (U), Information from A to Z metropolitan train (S), trams and buses. There are also special night buses (N) which may be used with the standard tickets. You can purchase public transportation tickets at most tobacconists (Tabak-Trafik), VOR ticket offices, ticket distributor machines at underground stations and in some hotels; on the tram (machine in the 1st coach) and on the bus (from the driver). Tickets must be stamped at the “blue box” located inside the tram or bus; for underground and metropolitan train it is located at the barrier before accessing the platform. Registration You can still register online and directly in Vienna. However, waiting can be eased, if participants register online in advance. Pre-registered participants will receive a barcode which is required on-site in order to print the badge. Therefore, it is essential to have the barcode ready. Self-printing stations are located directly in front of the registration desk. Registration Desk The registration desk is situated in the Hall on the ground floor. P: +43 1 536 44 223 Opening Hours WED, August 31 THU, September 1 FRI, September 2 SAT, September 3 12:00 PM–06:30 PM 07:00 AM–06:30 PM 07:00 AM–06:30 PM 07:00 AM–01:00 PM 9 CONGRESS INFORMATION Congress Information Information from A to Z CONGRESS INFORMATION © WienTourismus/Christian Stemper Congress Information Registration Fees Late/On-site Fees Delegates €665 Residents* €300 Students* €190 Accompanying person € 85 Day ticket €250 tavern (Heurigen) will deliver a marvellous atmosphere for the evening. You will appreciate the wonderful Viennese wines as well as various typical dishes. The bus-transfer to the location will start at 07:30 PM at Hofburg Vienna. *Proof of current status needs to be provided along with the registration. Smoking Smoking is strictly prohibited in the congress venue by law. Social Program Get Together The Get Together will take place on Wednesday, August 31 at 7:00 PM at the Hofburg Galerie in the Congress location. Time Zone Austria belongs to the Central European Time Zone (GMT+1). Networking Evening The Networking Evening will take place on Friday, September 2 at 08:00 PM. at Heuriger Werner Welser, Probusgasse 12, 1190 Vienna. The traditional Austrian Tipping In many areas such as gastronomy, in taxis, at hairdressers, at service stations, tipping is traditionally expected. Usually, the tip amounts to about 5 to 10%, according to the degree of your satisfaction with the service rendered. 10 Public Transport Vienna CONGRESS INFORMATION Congress Information 11 Hofburg Overview CONGRESS INFORMATION Congress Information Registration 1 Hofburg Foyer (Halle) Sessions 2Festsaal 3Zeremoniensaal 4Rittersaal 5 Geheime Ratstube 12 Industrial Exhibition 6 Hofburg Galerie 7Seitengalerie 8 Oberes Platzl Poster Exhibition 9Marmorsaal 10Antekammer Media Check 11Orchestergang EADO SCI ENTI FI C PRO G R A M Wednesday, August 31, 2016 14 Thursday, September 1, 2016 19 Friday, September 2, 2016 33 Saturday, September 3, 2016 49 List of Chairs and Speakers 54 Poster Exhibition 56 Scientific Program 04:00 PM WED THU 06:00 PM FRI 07:00 PM SAT Rittersaal SY3 Dermoscopy Part I Basics 01:30 PM–03:30 PM Geheime Ratstube 03:00 PM 05:00 PM 08:00 PM 09:00 PM POSTER INDEX Zeremoniensaal SY2 Biology of Skin Cancer Development 01:30 PM–03:30 PM 14 Coffe Break 03:30 PM–04:30 PM SAT2 SAT1 Novartis Symposium: Merck-Pfizer Symposium: Melanoma Changing Current and Potential Landscape: Individualized Future Treatment Options Decision Making for Merkel Cell Carcinoma 03:30 PM–04:30 PM 03:30 PM–04:30 PM PL1 Plenary 04:30 PM–06:00 PM OT1 Opening Ceremony 06:00 PM–07:00 PM OT2 Get Together (Hofburg Galerie) 07:00 PM–09:30 PM Exhibiton – Hofburg Galerie SCIENTIFIC PROGRAM Festsaal SY1 Epidemiology of Skin 02:00 PM Cancer, Public Education and Primary Prevention 01:30 PM–03:30 PM Wednesday, August 31, 2016 Scientific Program SY1 SYMPOSIUM Epidemiology of Skin Cancer, Public Education and Primary Prevention Festsaal P. Robins (USA) V. Del Marmol (Brussels, Belgium) 01:30 PM–01:50 PM SY1-1 Epidemiology of skin cancer worldwide A. Halpern (New York, USA) 01:50 PM–02:10 PM SY1-2 Skin cancer prevention in Australia M. Janda (Brisbane, Australia) 02:10 PM–02:30 PM SY1-3 Skin cancer prevention in the US A. Geller (Boston, USA) 02:30 PM–02:50 PM SY1-4 Euro-melanoma, a successful public awareness campaign V. Del Marmol (Brussels, Belgium) 02:50 PM–03:10 PM SY1-5 Is there a skin cancer epidemic in southern America F. Stengel (Buenos Aires, Argentina) 03:10 PM–03:30 PM SY1-6 Skin cancer in the Middle European region P. Arenberger (Prague, Czech Republic) 01:30 PM–03:30 PM SY2 SYMPOSIUM SCIENTIFIC PROGRAM Chairs: THU WED 01:30 PM–03:30 PM Wednesday, August 31, 2016 FRI Biology of Skin Cancer Development M. Herlyn (Philadelphia, USA) B. Lichtenberger (Vienna, Austria) 01:30 PM–01:50 PM SY2-1 UV and carcinogenesis – one source, many mechanisms T. Schwarz (Kiel, Germany) 01:50 PM–02:10 PM SY2-2 Identification of a novel mutational signature in cutaneous SCC associated with chronic azathioprine exposure G. Inman (Dundee, UK) 02:10 PM–02:30 PM SY2-3 RG1-VLP – a chimeric virus-like particle vaccine for prevention of HPV-associated cancers R. Kirnbauer (Vienna, Austria) 02:30 PM–02:50 PM SY2-4 Melanozytes – why they can give rise to deadly tumors M. Herlyn (Philadelphia, USA) 15 INDEX SAT Chairs: POSTER Zeremoniensaal SY2-5 Keratinocytes and autophagy – a role in carcinogenesis? E. Tschachler (Vienna, Austria) 03:10 PM–03:25 PM SY2-6 Do fibroblasts have a role in cutaneous carcinogenesis? B. Lichtenberger (Vienna, Austria) 01:30 PM–03:30 PM SY3 SYMPOSIUM Dermoscopy Part I Basics Rittersaal Chairs: I. Zalaudek (Graz, Vienna) H. Kittler (Vienna, Austria) 01:30 PM–01:50 PM SY3-1 The good: melanocytic nevi S. Puig (Barcelona, Spain) 01:50 PM–02:10 PM SY3-2 The bad: melanoma G. Argenziano (Napels, Italy) 02:10 PM–02:30 PM SY3-3 The ugly: seborrheic keratosis R. Hofmann-Wellenhof (Graz, Austria) 02:30 PM–02:50 PM SY3-4 The neglected: pigmented epithelial neoplasms I. Zalaudek (Graz, Austria) 02:50 PM–03:10 PM SY3-5 The hidden: non-pigmented neoplasms H. Kittler (Vienna, Austria) 03:10 PM–03:30 PM SY3-6 The eccentric: special sites J. Malvehy (Barcelona, Spain) SAT FRI Wednesday, August 31, 2016 02:50 PM–03:10 PM THU WED SCIENTIFIC PROGRAM Scientific Program POSTER INDEX 03:30 PM–04:30 PM 16 COFFEE BREAK Scientific Program SAT1 MERCK-PFIZER ALLIANCE SYMPOSIUM Lead: M. Locker (Chicago, USA) Chair: J. Becker (Essen, Germany) 03:30 PM–03:45 PM Welcome and introduction J. Becker (Essen, Germany) 03:45 PM–03:55 PM SAT1-1 Metastatic Merkel cell carcinoma: current treatment landscape C. Lebbé (Paris, France) 03:55 PM–04:20 PM SAT1-2 New treatment approaches for Merkel cell carcinoma I. Brownell (Bethesda, USA) SAT2 NOVARTIS SYMPOSIUM 03:30 PM–03:40 PM SAT2-1 Welcome and introduction. What have we learned from ASCO? J.- J. Grob (Marseille, France) 03:40 PM–04:00 PM SAT2-2 Primary and acquired resistance: What impact does this have on targeted and immunotherapies? J. Larkin (London, UK) 04:00 PM–04:20 PM SAT2-3 How can we use the data to individualize treatments? R. Gutzmer (Hannover, Germany) SAT J.-J. Grob (Marseille, France) INDEX Chair: FRI Melanoma Changing Landscape: Individualized Decision Making Rittersaal 04:20 PM–04:30 PM WED Q&A and close J. Becker (Essen, Germany) THU 04:20 PM–04:30 PM 03:30 PM–04:30 PM SCIENTIFIC PROGRAM Current and Potential Future Treatment Options for Merkel Cell Carcinoma Lunch boxes will be provided. Geheime Ratstube POSTER 03:30 PM–04:30 PM Wednesday, August 31, 2016 Panel discussion and Q&A 17 SCIENTIFIC PROGRAM Scientific Program Wednesday, August 31, 2016 04:30 PM–06:00 PM PL1 PLENARY LECTURE Festsaal Chairs: H. Pehamberger (Vienna, Austria) C. Hoeller (Vienna, Austria) K. Wolff (Vienna, Austria) 04:30 PM–05:15 PM PL1-1 Immunotherapy of melanoma – from revolution to evolution J. Weber (New York, USA) 05:15 PM–06:00 PM PL1-2 Targeted therapy of basal cell carcinoma – past, present and the future A. Sekulic (Phoenix, USA) 06:00 PM–07:00 PM OT1 OPENING CEREMONY Hubert Pehamberger, Congress President Festsaal Claus Garbe, President EADO WED Phili-Tango - Ensemble with members of the Vienna Philharmonic Orchestra FRI Markus Mueller, Rector Medical University of Vienna THU Perry Robins, President Skin Cancer Foundation 07:00 PM–09:30 PM POSTER INDEX SAT Hofburg Galerie 18 OT2 GET TOGETHER 08:00 AM Festsaal SY4 Genetic Testing in Skin Cancer – Methods and Strategies 08:00 AM–08:55 AM 09:00 AM 10:00 AM 11:00 AM SY8 Melanoma Therapy Drugs and Trials Current Status I – Kinase Inhibitors 09:30 AM–10:55 AM Thursday, September 1, 2016 Zeremoniensaal SY5 Cutaneous Lymphoma I Biology, Epidemiology, Genetic Research 08:00 AM–08:55 AM Coffee Break 09:00 AM–09:30 AM Rittersaal SY6 Skin Cancer Centers – What is the Worldwide Standard? 08:00 AM–08:55 AM SY10 BCC Epidemiology, Biology, Genetics, Clinical Data 09:30 AM–10:55 AM SY9 Surgery of Skin Cancer Primaries 09:30 AM–10:55 AM Geheime Ratstube SY7 Basics of (Cutaneous) Immunology 08:00 AM–08:55 AM SCIENTIFIC PROGRAM Scientific Program SAT3 LEO Pharma Breakfast Symposium: More than Meets the Eye 9:00 AM–10:00 AM SY11 Skin Cancer Biology 10:00 AM–10:55 AM PL2 Genetics 11:00 AM–12:00 PM SY15 Sentinel Node Surgery 01:30 PM–02:50 PM SAT5 F. Hoffmann – La Roche Vienna Coffeehouse Symposium: “Advanced melanoma: Treat it personally” 03:00 PM–04:00 PM Coffee Break 03:00 PM–04:15 PM 04:00 PM PL3 Plenary Melanoma 04:15 PM–05:15 PM 05:00 PM SY16 Controversies: Is Immunotherapy the Current Standard for Every 06:00 PM Melanoma Patient? 05:20 PM–06:20 PM SY17 PDT 05:20 PM–06:20 PM WED THU INDEX 03:00 PM SY14 Open Questions in Dermatopathology of Cutaneous Tumors 01:30 PM–02:50 PM POSTER 02:00 PM SY12 SY13 Melanoma Therapy Drugs Squamous Cell Carcinoma/ and Trials Current Status AK – Epidemiology, II – Immunotherapy Biology, Local Therapies 01:30 PM–02:50 PM 01:30 PM–02:50 PM FRI 01:00 PM Lunch Break 12:00 PM–01:30 PM SAT SAT4 AMGEN Lunch Symposium: Advancing Immuno-Oncology with an Intralesional Treatment 12:15 PM–01:15 PM Exhibiton – Hofburg Galerie 12:00 PM SY18 Vaccines for Cutaneous Tumors 05:20 PM–06:20 PM 19 Scientific Program 08:00 AM–08:55 AM SY4 SCIENTIFIC PROGRAM J. Malvehy (Barcelona, Spain) M. C. Fargnoli (L’Aquila, Italy) 08:00 AM–08:25 AM SY4-1 Genetic testing in skin cancer – from specific to abundant G. McArthur (Melbourne, Australia) 08:25 AM–08:40 AM SY4-2 Genetic testing in daily practice – what’s feasible? M. C. Fargnoli (L’Aquila, Italy) 08:40 AM–08:55 AM SY4-3 Genetic testing for skin cancer susceptibility – did we come to an end? I. Okamoto (Vienna, Austria) 08:00 AM–08:55 AM SY5 SYMPOSIUM Cutaneous Lymphoma I Biology, Epidemiology, Genetic Research Zeremoniensaal Chairs: J. Scarisbrick (Birmingham, UK) P. Quaglino (Torino, Italy) 08:00 AM–08:13 AM SY5-1 Pathogenetic concepts in T-cell lymphoma 2016 S. Whittaker (London, UK) 08:13 AM–08:26 AM SY5-2 Sezary Syndrom and the EORTC translational research projects 2016 M. H. Vermeer (Leiden, Netherlands) 08:26 AM–08:39 AM SY5-3 Results of the cutaneous lymphoma prognostic study (CLIPI) J. Scarisbrick (Birmingham, UK) 08:39 AM–08:55 AM SY5-4 The new WHO 2015 classification of cutaneous lymphomas R. Willemze (Leiden, Netherlands) THU WED Chairs: INDEX SAT FRI SYMPOSIUM Genetic Testing in Skin Cancer – Methods and Strategies Festsaal POSTER Thursday, September 1, 2016 20 Scientific Program SY6 SYMPOSIUM Skin Cancer Centers – What is the Worldwide Standard? Rittersaal A.-M. Forsea (Bucharest, Romania) P. Mohr (Buxtehude, Germany) 08:00 AM–08:15 AM SY6-1 What should an ideal skin cancer center look like? P. Mohr (Buxtehude, Germany) 08:15 AM–08:30 AM SY6-2 What can we achieve in the light of current limitations? A.-M. Forsea (Bucharest, Romania) 08:30 AM–08:45 AM SY6-3 How can interdisciplinary cooperation maximize our patients benefit? C. Hoeller (Vienna, Austria) 08:45 AM–08:55 AM SY6-4 Panel discussion: What do we have to do to maximize patient benefit and research output in skin cancer centers? 08:00 AM–08:55 AM SY7 SYMPOSIUM WED Chairs: SCIENTIFIC PROGRAM 08:00 AM–08:55 AM Thursday, September 1, 2016 Principles of cutaneous immunology S. Grabbe (Mainz, Germany) 08:25 AM–08:40 AM SY7-2 Trafficking of immune cells in the skin, implications for therapy W. Weninger (Sidney, Australia) 08:40 AM–08:55 AM SY7-3 The emerging role of resident memory T cells in protective immunity and inflammatory disease T. Kupper (Boston, USA) 09:00 AM–09:30 AM FRI SY7-1 SAT 08:00 AM–08:25 AM INDEX W. Weninger (Sidney, Australia) S. Grabbe (Mainz, Germany) POSTER Chairs: THU Basics of (Cutaneous) Immunology Geheime Ratstube COFFEE BREAK 21 KEYTRUDA 10 mg/kg Q3W KEYTRUDA 10 mg/kg Q2W Ipilimumab 0.69 (0.52–0.90) 0.63 (0.47–0.83) HR (95% CI) vs ipilimumab Kaplan-Meier curve for overall survival by treatment arm. 31% 37% Risk reduction vs ipilimumab 0.00358 0.00052 P value 68% 1-year estimated overall survival rate vs 58% with ipilimumaba,b The first anti–PD-1 to demonstrate superior overall survival vs ipilimumab START WITH KEYTRUDA For patients with advanced melanoma Copyright © 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. 06-17-ONCO-1188131-0000. Erstellt: Juni 2016 For further Information on Posology and method of administration, Special warnings and precautions for use, Interaction with other medicinal products and other forms of interaction, Effects on ability to drive and use machines, Undesirable effects, Overdose, Pharmacodynamic properties and Pharmacokinetic properties refer to the published summary of product characteristics. SUMMARY OF PRODUCT CHARACTERISTICS: Name of the Medicinal Product KEYTRUDA® 50 mg powder for concentrate for solution for infusion. Qualitative and Quantitative Composition One vial of powder contains 50 mg of pembrolizumab. After reconstitution, 1 ml of concentrate contains 25 mg of pembrolizumab. Pembrolizumab is a humanised monoclonal anti-programmed cell death-1 (PD-1) antibody (IgG4/kappa isotype with a stabilising sequence alteration in the Fc region) produced in Chinese hamster ovary cells by recombinant DNA technology. List of excipients L-Histidine, L-Histidine hydrochloride Monohydrate, Sucrose, Polysorbate 80 Therapeutic indications KEYTRUDA® as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Fertility, pregnancy and lactation Pregnancy There are no data on the use of pembrolizumab in pregnant women. Animal reproduction studies have not been conducted with pembrolizumab; however, in murine models of pregnancy blockade of PD-L1 signaling has been shown to disrupt tolerance to the foetus and to result in an increased foetal loss. These results indicate a potential risk, based on its mechanism of action, that administration of pembrolizumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth. Human immunoglobulins G4 (IgG4) are known to cross the placental barrier and pembrolizumab is an IgG4; therefore, pembrolizumab has the potential to be transmitted from the mother to the developing foetus. Pembrolizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with pembrolizumab. Women of childbearing potential should use effective contraception during treatment with pembrolizumab and for at least 4 months after the last dose of pembrolizumab. Breast-feeding It is unknown whether pembrolizumab is secreted in human milk. Since it is known that antibodies can be secreted in human milk, a risk to the newborns/infants cannot be excluded. A decision should be made whether to discontinue breast-feeding or to discontinue pembrolizumab, taking into account the benefit of breast-feeding for the child and the benefit of pembrolizumab therapy for the woman. Fertility No clinical data are available on the possible effects of pembrolizumab on fertility. Although reproductive and developmental toxicity studies have not been conducted with pembrolizumab, there were no notable effects in the male and female reproductive organs in monkeys based on 1-month and 6-month repeat dose toxicity studies. Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. ATC code: L01XC18 Marketing Authorisation Holder Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom Dispensing: available only on prescription and only in pharmacies. Information as of: April 2016 Before prescribing KEYTRUDA®, please read the Prescribing Information. Reference: 1. Robert C, Schachter J, Long GV, et al, for the KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. KEYTRUDA® is indicated for the treatment of patients with unresectable or metastatic melanoma. a In intent-to-treat population. bMedian not reached. PD-1=programmed death receptor-1; Q3W=every 3 weeks; Q2W=every 2 weeks; HR=hazard ratio; CI=confidence interval. KEYNOTE-006 study design: An open-label, multicenter, randomized, controlled Phase 3 trial that included patients with unresectable or metastatic melanoma who were naïve to ipilimumab and who had received no more than 1 prior systemic therapy. Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy. Patients were randomized (1:1:1) to receive KEYTRUDA® at a dose of 10 mg/kg every 2 (n=279) or 3 weeks (n=277) or ipilimumab (n=278). The primary efficacy outcome measures were overall survival (OS) and progression-free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]).1 Scientific Program 09:00 AM–10:00 AM SAT3 SCIENTIFIC PROGRAM Chair: 09:00 AM–09:15 AM C. Garbe (Tuebingen, Germany) Welcome and introduction C. Garbe (Tuebingen, Germany) 09:15 AM–09:30 AM SAT3-1 What lies beneath? Optimising diagnosis of field cancerisation I. Zalaudek (Graz, Austria) 09:30 AM–09:45 AM SAT3-2 AK and beyond: Tailored therapy to optimise patient outcomes J.-J. Grob (Marseille, France) 09:45 AM–09:55 AM SAT3-3 Panel discussion 09:55 AM–10:00 AM WED LEO-PHARMA BREAKFAST SYMPOSIUM More than Meets the Eye – Treating Actinic Keratosis (AK) and Beyond Geheime Ratstube 09:30 AM–10:55 AM Closing remarks and wrap up C. Garbe (Tuebingen, Germany) SY8 SYMPOSIUM Melanoma Therapy Drugs and Trials Current Status I – Kinase Inhibitors A. Hauschild (Kiel, Germany) FRI 09:30 AM–09:47 AM SY8-1 Vem/Cobimetinib G. McArthur (Melbourne, Australia) 09:47 AM–10:04 AM SY8-2 Dabrafenib/Trametinib A. Hauschild (Kiel, Germany) 10:04 AM–10:21 AM SY8-3 Kinase inhibitors for N-ras mutated patients J.-J. Grob (Marseille, France) 10:21 AM–10:38 AM SY8-4 Kinase inhibitors for rare mutation subgroups D. Schadendorf (Essen, Germany) 10:38 AM–10:55 AM SY8-5 Identification of prognostic subgroups for overall survival in patients (pts) with BRAFV600-mutated metastatic melanoma treated with vemurafenib ± cobimetinib: a pooled exploratory analysis of the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies A. Hauschild (Kiel, Germany) POSTER Chair: SAT Festsaal INDEX THU Thursday, September 1, 2016 24 Scientific Program SY9 SYMPOSIUM F. Roka (Vienna, Austria) R. Kaufmann (Frankfurt, Germany) 09:30 AM–09:50 AM SY9-1 Current standards for the management of primary skin cancer lesions in Europe R. Kaufmann (Frankfurt, Germany) 09:50 AM–10:10 AM SY9-2 Current standards for the management of primary skin cancer lesions in the US J. Gershenwald (Houston, USA) 10:10 AM–10:30 AM SY9-3 The role of mohs surgery in the management of primary skin cancer lesions J. Alcalay (Tel Aviv, Israel) 10:30 AM–10:55 AM SY9-4 Managment of primary lesions of rare skin tumors F. Roka (Vienna, Austria) 09:30 AM–10:55 AM SY10 SYMPOSIUM WED Chairs: SCIENTIFIC PROGRAM Surgery of Skin Cancer Primaries Rittersaal BCC Epidemiology, Biology, Genetics, Clinical Data Zeremoniensaal THU 09:30 AM–10:55 AM Thursday, September 1, 2016 H. Hahn (Tuebingen, Germany) R. Kunstfeld (Vienna, Austria) 09:30 AM–09:50 AM SY10-1 Man’s most common tumor – the BCC epidemic A. Stratigos (Athens, Greece) 09:50 AM–10:10 AM SY10-2 Gorlin-Goltz syndrom H. Hahn (Tuebingen, Germany) 10:10 AM–10:25 AM SY10-3 Which open questions in BCC biology will we have to answer in the future? A. Sekulic (Phoenix, USA) 10:25 AM–10:40 AM SY10-4 Use of vismodegib in the real world: analysis of a US insurance claims database C. Sima (San Francisco, USA) 10:40 AM–10:55 AM SY10-5 Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis R. Dummer (Zuerich, Switzerland) POSTER INDEX SAT FRI Chairs: 25 Scientific Program 10:00 AM–10:55 AM SY11 SCIENTIFIC PROGRAM Chairs: V. Paulitschke (Vienna, Austria) D. Schramek (Toronto, Canada) 10:00 AM–10:20 AM SY11-1 The role of ETS transcription factors in SCC development D. Schramek (Toronto, Canada) 10:20 AM–10:40 AM SY11-2 Defining the mode of melanoma heterogeneity and drug sensitivity by real-time cell cycle imaging N. Haass (Queensland, Australia) 10:40 AM–10:55 AM SY11-3 Proteomics to reveal resistance mechanisms beyond genetic changes V. Paulitschke (Vienna, Austria) 11:00 AM–12:00 PM PL2 PLENARY LECTURE Genetics Festsaal Chairs: A. Halpern (New York, USA) C. Garbe (Tuebingen, Germany) 11:00 AM–11:30 AM PL2-1 Genetics of Nevi – what do they tell us about melanoma? B. Bastian (San Francisco, USA) 11:30 AM–12:00 AM PL2-2 Mutanome specific personalized vaccination U. Sahin (Mainz, Germany) SAT FRI THU WED SYMPOSIUM Skin Cancer Biology Geheime Ratstube 12:00 PM–01:30 PM POSTER INDEX Thursday, September 1, 2016 26 LUNCH BREAK Scientific Program SAT4 AMGEN LUNCH SYMPOSIUM Advancing Immuno-Oncology with an Intralesional Treatment Chair: 12:15 PM–12:20 PM H. Pehamberger (Vienna, Austria) SCIENTIFIC PROGRAM Zeremoniensaal Welcome and introduction H. Pehamberger (Vienna, Austria) 12:20 PM–12:40 PM SAT4-1 Igniting the immune response to target the tumor C. Hoeller (Vienna, Austria) 12:40 PM–01:00 PM SAT4-2 Talimogene laherparepvec (‘T-VEC’)* in clinical practice O. Michielin (Geneva, Switzerland) 01:00 PM–01:10 PM Q&A 01:10 PM–01:15 PM Summary and close SY12 SYMPOSIUM THU 01:30 PM–02:50 PM WED * ▼ Subject to additional monitoring. This will allow quick identification of new safety information. Melanoma Therapy Drugs and Trials Current Status II – Immunotherapy Festsaal B. Dreno (Nantes, France) J. Weber (Tampa, USA) 01:30 PM–01:50 PM SY12-1 PD-1 R. Dummer (Zuerich, Switzerland) 01:50 PM–02:10 PM SY12-2 Vaccines and cell based therapies B. Dreno (Nantes, France) 02:10 PM–02:30 PM SY12-3 Novel immunotherapies and combinations J. Weber (Tampa, USA) 02:30 PM–02:40 PM SY12-4 Efficacy and quality of life outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase III trial (CheckMate 067) D. Schadendorf (Essen, Germany) 02:40 PM–02:50 PM SY12-5 Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB–IVM1a melanoma in the OPTiM phase III trial K. Harrington (London, UK) INDEX SAT FRI Chairs: 27 POSTER 12:15 PM–01:15 PM Thursday, September 1, 2016 Scientific Program 01:30 PM–02:50 PM SY13 SCIENTIFIC PROGRAM WED THU SYMPOSIUM Squamous Cell Carcinoma/AK-Epidemiology, Biology, Local Therapies Zeremoniensaal Chairs: A. Handisurya (Vienna, Austria) G. Hofbauer (Zuerich, Switzerland) 01:30 PM–01:45 PM SY13-1 From UV to SCC – insights into the biology of field cancerization E. Stockfleth (Bochum, Germany) 01:45 PM–02:00 PM SY13-2 Beyond UV – viral carcinogenesis in SCC A. Handisurya (Vienna, Austria) 02:00 PM–02:20 PM SY13-3 Topical therapy of NMSC R. Kunstfeld (Vienna, Austria) 02:20 PM–02:35 PM SY13-4 Outcome evaluation of local therapies – which endpoints show the real effect? G. Hofbauer (Zuerich, Switzerland) 02:35 PM–02:50 PM SY13-5 Structured expert consensus on actinic keratosis: an up-to-date treatment algorithm P. Calzavara-Pinton (Brescia, Italy) 01:30 PM–02:50 PM SY14 SYMPOSIUM Open Questions in Dermatopathology of Cutaneous Tumors FRI Rittersaal M. C. Mihm (Boston, USA) P. Petzelbauer (Vienna, Austria) 01:30 PM–01:55 PM SY14-1 Open questions in the histopathology of cutaneous tumors 2016 M. C. Mihm (Boston, USA) 01:55 PM–02:13 PM SY14-2 Desmoplastic melanoma K. J. Busam (New York, USA) 02:13 PM–02:31 PM SY14-3 Spitzoid melanocytic neoplasms R. L. Barnhill (Paris, France) 02:31 PM–02:50 PM SY14-4 Open questions and standards in the pathology of cutaneous SCC A. Sober (Boston, USA) SAT Chairs: INDEX POSTER Thursday, September 1, 2016 28 Scientific Program SY15 SYMPOSIUM Chairs: A. Testori (Milano, Italy) M. Gnant (Vienna, Austria) 01:30 PM–01:50 PM SY15-1 Sentinel node in melanoma – the evidence behind the method M. Ross (Houston, USA) 01:50 PM–02:10 PM SY15-2 Lessons learned from sentinel node in breast cancer M. Gnant (Vienna, Austria) 02:10 PM–02:30 PM SY15-3 Do we need to perform CLND after sentinel? C. Garbe (Tuebingen, Germany) 02:30 PM–02:50 PM SY15-4 Sentinel node in skin cancer beyond melanoma J. Gershenwald (Houston, USA) 03:00 PM–04:15 PM F. HOFFMANN-LA ROCHE LTD. VIENNA COFFEEHOUSE SYMPOSIUM J. Larkin (London, UK) 03:00 PM–03:15 PM SAT5-1 The current treatment landscape in advanced melanoma” J. Larkin (London, UK) 03:15 PM–03:55 PM SAT5-2 Summary and close J. Larkin (London, UK) INDEX Chair: SAT Advanced melanoma: Treat it personally Optimising outcomes with targeted therapies in advanced melanoma in your clinical practice Zeremoniensaal THU SAT5 WED COFFEE BREAK POSTER 03:00 PM–04:00 PM SCIENTIFIC PROGRAM Setinel Node Surgery Geheime Ratstube FRI 01:30 PM–02:50 PM Thursday, September 1, 2016 29 Scientific Program 04:15 PM–05:15 PM PL3 PLENARY LECTURE Melanoma Festsaal SCIENTIFIC PROGRAM Thursday, September 1, 2016 Chairs: D. Schadendorf (Essen, Germany) G. McArthur (Brisbane, Australia) 04:15 PM–04:45 PM PL3-1 Combination therapies for skin cancer – where do we go? C. Blank (Amsterdam, Netherlands) 04:45 PM–05:15 PM PL3-2 Biomarkers for melanoma treatment – how will they impact our treatment decisions? O. Michielin (Lausanne, Switzerland) 05:20 PM–06:20 PM SY16 SYMPOSIUM Controversies: Is Immunotherapy the Current Standard for Every Melanoma Patient? Pro/Con R. Dummer (Zuerich, Switzerland) P. Arenberger (Prague, Czech Republic) 05:20 PM–05:40 PM SY16-1 Pro J. Larkin (London, UK) THU 05:40 PM–06:00 PM SY16-2 Contra O. Michielin (Lausanne, Switzerland) 06:00 PM–06:20 PM 05:20 PM–06:20 PM POSTER Discussion with the audience SY17 SYMPOSIUM PDT Zeremoniensaal Chairs: S. Radakovic (Vienna, Austria) R.-M. Szeimies (Recklinghausen, Germany) 05:20 PM–05:35 PM SY17-1 Topical photodynamic therapy in dermatology – how does it work? L. Braathen (Bern, Switzerland) 05:35 PM–05:50 PM SY17-2 PDT for skin cancer – what should we treat and what not? E. Sotiriou (Thessaloniki, Greece) 05:50 PM–06:05 PM SY17-3 Day-light PDT – a major breakthrough in dermatological PDT? R.-M. Szeimies (Recklinghausen, Germany) 06:05 PM–06:20 PM SY17-4 PDT-associated pain – are there means for relief? S. Radakovic (Vienna, Austria) INDEX SAT WED Chairs: FRI Festsaal 30 Read JDDG on the Go App available for iPad®, iPhone® and iPod Touch® Experience an entirely new browsing and reading experience • Convenient access to articles anytime, anywhere • Quick navigation to any section of the app • Immediate access to new content • Select keywords for tailored content alerts • Downloadissuestoreadoffline,orshareimportantarticles • Enhanced search across all downloaded content Scan the QR code, or visit your App Store® online to download the app today 239807 • Sync your favorite app content across devices via iCloud® Scientific Program 05:20 PM–06:20 PM SY18 SCIENTIFIC PROGRAM SYMPOSIUM Vaccines for Cutaneous Tumors Rittersaal Chairs: U. Sahin (Mainz, Germany) G. Schuler (Erlangen, Germany) 05:20 PM–05:40 PM SY18-1 Vaccines for melanoma – time for a comeback? G. Schuler (Erlangen, Germany) 05:40 PM–06:00 PM SY18-2 Oncolytic viruses: vehicles for endogenus vaccination? R. Andtbacka (Salt Lake City, USA) 06:00 PM–06:20 PM SY18-3 RNA based mutanome specific vaccines – a true personalized therapy U. Sahin (Mainz, Germany) 05:20 PM–06:20 PM PW1 POSTERWALK Marmorsaal/ Antekammer POSTER INDEX SAT FRI THU WED Thursday, September 1, 2016 32 Melanoma P001- P099 Late-Breaking P206 - P219 Scientific Program 09:00 AM 10:00 AM 11:00 AM Festsaal SY19 Controversies: Is there a Dysplastic Nevus? 08:00 AM–08:55 AM SY22 Neo-adjuvant Treatment in Skin Cancer Patients 09:00 AM–10:30 AM Zeremoniensaal Rittersaal SY20 SY21 Chemotherapy of Skin Cutaneous Side Effects Cancers – Does it Still of Oncological Drugs Have a Role in Our 08:00 AM–08:55 AM Algorithms? 08:00 AM–08:55 AM SY23 SY24 Cutaneous Lymphoma II – Genetics of Skin Cancer Therapy Update 09:00 AM–10:30 AM 09:00 AM–10:30 AM Coffee Break 10:30 AM–11:00 AM Geheime Ratstube FC1 Free Communications: Melanoma 08:00 AM–08:55 AM SCIENTIFIC PROGRAM 08:00 AM Friday, September 2, 2016 SY25 Dermosocopy II Experts 09:00 AM–10:30 AM PL4 Cutaneous Lymphoma, New Drugs 11:00 AM–12:00 PM 04:00 PM 05:00 PM SY30 UV-Protection, Vitamin D and Photoaging 04:05 PM–05:25 PM SY34 Controversies: Sentinel Node and Completion 06:00 PM Lymph Node Dissection – Standard of Care? 05:30 PM–06:30 PM 08:00 PM SY35 Skin Cancer in Special Patient Subgroups 05:30 PM–06:30 PM WED THU SY29 What’s a Drugs Value? 01:30 PM–02:50 PM FRI 03:00 PM SY28 Tumor Immunology 01:30 PM–02:50 PM Coffee Break 03:00 PM–04:00 PM SY32 Smart Sequencing or Combination Therapy – in Search for the Best Strategy 04:05 PM–05:25 PM SY36 Locoregional Therapy of Melanoma Metastases 05:30 PM–06:30 PM SAT SY26 How to Overcome Drug Resistance 01:30 PM–02:50 PM INDEX 02:00 PM Lunch Break/Exhibition 12:00 PM–01:15 PM SY33 Orphan Skin Cancer – Epidemiology, Histopathology, Biology, Therapy 04:05 PM–05:25 PM SY37 Psychodermatooncology 05:30 PM–06:30 PM POSTER 01:00 PM SAT6 Lunch Symposium Bristol-Myers Squibb: Immuno Oncology for Melanoma: What’s new? 12:15 AM–01:15 PM SY27 Systemic Treatment of Non-Melanoma Skin Cancer 01:30 PM–02:50 PM SAT7 MSD Vienna Coffeehouse Symposium: Great Debates of ImmunoOncology Therapies in Advanced Melanoma 03:00 PM–04:00 PM SY31 Melanoma Surgery Lymph Nodes to Distant 04:05 PM–05:25 PM Exhibiton – Hofburg Galerie 12:00 PM OT3 Networking Evening (Heuriger) 08:00 PM 33 CURRENTLY ENROLLING: JAVELIN Merkel 200 (First-line Cohort) A Phase 2, open-label, multicenter trial to investigate the clinical activity and safety of avelumab* (MSB0010718C) in subjects with metastatic Merkel cell carcinoma FOR MORE INFORMATION: www.clinicaltrials.gov (NCT02155647) The JAVELIN clinical trial program studies avelumab in Phases 1-3, both as monotherapy and in combination with other agents. The program includes diseases with large patient populations as well as rare diseases with high unmet needs. Trials are currently enrolling patients with†: • Merkel Cell Carcinoma (MCC) • Hodgkin’s lymphoma • Renal Cell Carcinoma (RCC) • Melanoma • Non-Small Cell Lung Cancer (NSCLC) • Squamous Cell Carcinoma of the Head and Neck (SCCHN) • Ovarian cancer • Adenocarcinoma of the stomach or of the gastroesophageal junction • Urothelial cancer Avelumab is an investigational agent. *Avelumab is the nonproprietary name for the anti-PD-L1 monoclonal antibody (MSB0010718C). † NCT02155647, NCT02603419, NCT02684006, NCT02493751, NCT02554812, NCT02395172, NCT02576574, NCT02584634, NCT02580058, NCT02625610, NCT02625623, NCT01772004, NCT02603432 This information is current as of June 2016. June 2016 US-AVL-0116-0004(1) Scientific Program SY19 SYMPOSIUM Chairs: P. Tschandl (Vienna, Austria) C. Hoeller (Vienna, Austria) 08:00 AM–08:20 AM SY19-1 Pro B. Bastian (San Francisco, USA) 08:20 AM–08:40 AM SY19-2 Contra H. Kittler (Vienna, Austria) 08:40 AM–08:55 AM Discussion with the audience SY20 SYMPOSIUM SY20-1 Chemotherapy for melanoma – last resort or still an option? P. Lorigan (Manchester, UK) 08:13 AM–08:26 AM SY20-2 Chemotherapy for metastatic SCC R. Gutzmer (Hanover, Germany) 08:26 AM–08:39 AM SY20-3 Chemotherapy for cutaneous lymphomas L. Geskin (New York, USA) 08:39 AM–08:55 AM SY20-4 Chemotherapy in the treatment of orphan skin cancers R. Loewe (Vienna, Austria) 08:00 AM–08:55 AM SY21 SYMPOSIUM THU 08:00 AM–08:13 AM FRI P. Lorigan (Manchester, UK) R. Gutzmer (Hanover, Germany) SAT Chairs: WED Chemotherapy of Skin Cancers – Does It Still Have a Role in Our Algorithms? Zeremoniensaal INDEX 08:00 AM–08:55 AM SCIENTIFIC PROGRAM Controversies: Is There a Dysplastic Nevus? Festsaal POSTER 08:00 AM–08:55 AM Friday, September 2, 2016 Cutaneous Side Effects of Oncological Drugs Rittersaal Chairs: C. Lebbé (Paris, France) V. Sibaud (Toulouse, France) 08:00 AM–08:30 AM SY21-1 Cutaneous side effects of drugs in general oncology V. Sibaud (Toulouse, France) 08:30 AM–08:55 AM SY21-2 Cutaneous side effects of novel PI3K inhibitors in mono- and combination-therapy K. Schindler (Vienna, Austria) 35 Scientific Program 08:00 AM–08:55 AM FC1 SCIENTIFIC PROGRAM WED P. Petzelbauer (Vienna, Austria) M. Herlyn (Philadelphia, USA) 08:00 AM–08:12 AM FC1-1 The role of the lymphovasculature during skin cancer development P. Petzelbauer (Vienna, Austria) 08:12 AM–08:24 AM FC1-2 Wnt signalling as a metabolic regulator in melanoma cells V. Sherwood (Dundee, UK) 08:24 AM–08:36 AM FC1-3 Modeling Wnt secretion in cutaneous squamous cell carcinoma K. I. Kober (Heidelberg, Germany) 08:36 AM–08:48 AM FC1-4 Upregulated sonic hedgehog activity drives the development of congenital nevi A. Chitsazan (Herston/Brisbane, Australia) 08:48 AM–08:55 AM FC1-5 Understanding benign T-cell infiltration in mycosis fungoides: Malignant clones are not lone P. A. Vieyra-Garcia (Graz/Boston, Austria, MA; USA) 09:00 AM–10:30 AM SY22 SYMPOSIUM FRI THU Chairs: Neo-adjuvant Treatment in Skin Cancer Patients Festsaal Chairs: H. Pehamberger (Vienna, Austria) H. Gogas (Athens, Greece) 09:00 AM–09:20 AM SY22-1 From adjuvant to neo-adjuvant treatment in skin cancers – time to change the paradigm? J.-J. Grob (Marseille, France) 09:20 AM–09:40 AM SY22-2 Can biomarkers help us to select patients for neo‑adjuvant treatment? H. Gogas (Athens, Greece) 09:40 AM–10:00 AM SY22-3 Neoadjuvant treatment in melanoma – a useful strategy? J. Kirkwood (Pittsburgh, USA) 10:00 AM–10:30 AM SY22-4 Surgical strategies to maximize the outcome of neo-adjuvant treatment A. Testori (Milano, Italy) SAT INDEX FREE COMMUNICATIONS Melanoma Geheime Ratstube POSTER Friday, September 2, 2016 36 Scientific Program SY23 SYMPOSIUM 09:00 AM–09:15 AM SY23-1 EORTC treatment guidelines 2015 F. Trautinger (St. Poelten, Austria) 09:15 AM–09:30 AM SY23-2 Use of alemtuzumab and radiation therapy in CTCL R. A. Clark (Boston, USA) 09:30 AM–09:45 AM SY23-3 Mogamolizumab in CTCL M. Duvic (Houston, USA) 09:45 AM–10:00 AM SY23-4 Treatment update on b-cell lymphomas M. Bagot (Paris, France) 10:00 AM–10:15AM SY23-5 Brentuximab vendotin in CTCL R. Stadler (Minden, Germany) 10:15 AM–10:30 AM SY23-6 Photopheresis in CTCL R. Knobler (Vienna, Austria) 09:00 AM–10:30 AM SY24 SYMPOSIUM WED L. Geskin ( New York, USA) L. Papadavid (Ort, Greece) THU Chairs: SCIENTIFIC PROGRAM Cutaneous Lymphoma II – Therapy Update Zeremoniensaal 09:00 AM–09:20 AM SY24-1 Genetics of melanocytic tumors – from benign to malignant B. Bastian (San Francisco, USA) 09:20 AM–09:40 AM SY24-2 Genetic background and UV – how do they cooperate to form skin cancer? N. Hayward (Brisbane, Australia) 09:40 AM–10:00 AM SY24-3 Acquired mutations in melanoma, B-raf and beyond G. McArthur (Brisbane, Australia) 10:00 AM–10:30 AM SY24-4 The role of telomers in skin tumors R. Kumar (Heidelberg, Germany) SAT I. Okamoto (Vienna, Austria) B. Bastian (San Francisco, USA) INDEX Chairs: FRI Genetics of Skin Cancer Rittersaal POSTER 09:00 AM–10:30 AM Friday, September 2, 2016 37 Scientific Program 09:00 AM–10:30 AM SY25 SCIENTIFIC PROGRAM WED THU Chairs: W. Stolz (Munich, Germany) C. Rosendahl (Brisbane, Australia) 09:00 AM–09:15 AM SY25-1 Challenging cases W. Stolz (Munich, Germany) 09:15 AM–09:30 AM SY25-2 Twin cases P. Tschandl (Vienna, Austria) 09:30 AM–09:45 AM SY25-3 Nail cases L. Thomas (Lyon, France) 09:45 AM–10:00 AM SY25-4 Non-pigmented cases C. Rosendahl (Brisbane, Australia) 10:00 AM–10:15 AM SY25-5 Unusual cases H. Kittler (Vienna, Austria) 10:15 AM–10:30 AM SY25-6 Challenging high risk patients S. Puig (Barcelona, Spain) 10:30 AM–11:00 AM 11:00 AM–12:00 PM COFFEE BREAK PL4 PLENARY LECTURE Cutaneous Lymphoma, New Drugs Festsaal Chairs: R. Knobler (Vienna, Austria) J. Kirkwood (Pittsburgh, USA) 11:00 AM–11:30 AM PL4-1 New insights in understanding T-cell biology in cutaneous lymphoma R. Clark (Boston, USA) 11:30 AM–12:00 PM PL4-2 New therapies – price vs. value – can we afford it? J. Larkin (London, UK) INDEX SAT FRI SYMPOSIUM Dermosocopy II Experts Geheime Ratstube POSTER Friday, September 2, 2016 12:00 PM–01:15 PM 38 LUNCH BREAK Actinic Keratosis Editors: H. Peter Soyer Tarl W. Prow Gregor B.E. Jemec Current Problems in Dermatology, Vol. 46 Actinic Kreatosis VIII + 154 p., 33 fig., 29 in color, 4 tab., 2015 CHF 189.00 / EUR 177.00 / USD 222.00 (hard cover or online*) ISBN 978–3–318–02762–4 e th th at oo e b bl ss la e ai epr Av is W Extraordinary insights into an ordinary pathology Current Problems in Dermatology Editors: P. Itin, G.B.E. Jemec Vol. 46 Actinic Keratosis Editors H.P. Soyer T.W. Prow G.B.E. Jemec Renowned experts present the latest knowledge Skin Barrier Function Current Problems in Dermatology Editors: P. Itin, G.B.E. Jemec Vol. 49 Skin Barrier Function Editor Editor: Tove Agner Current Problems in Dermatology, Vol. 49 Skin Barrier Function VIII + 164 p., 26 fig., 6 in color, 14 tab., 2016 CHF 179.00 / EUR 167.00 / USD 211.00 (hard cover or online*) ISBN 978–3–318–05585–6 *online prices for personal customers Prices subject to change, VAT not included EUR price for eurozone countries, USD price for USA and Latin America only Order at: www.karger.com/cupde orders@karger.com KI16406 T. Agner 25 O S S E R NG TH C V D A E GY OLO RE VENE 16 0 2 R D Y OF TOBE C ADEM C O A - 2 , VIENNA PEAN R E EURO B EM RIA CENTER TRIA T P E AUST 28 S , AUa2S016.org A N VIEwN.eadvvienn ND GY A TOLO ERMA ww Join us in Vien n for the TaH 25 EADV Congre ss Scientific Program SAT6 BRISTOL-MYERS SQUIBB LUNCH SYMPOSIUM Immuno Oncology for Melanoma: What’s New? Chair: Welcome and introduction C. Hoeller (Vienna, Austria) 12:20 PM–12:30 PM SAT6-1 Melanoma 2016: Recent data and clinical implications J. Weber (New York, USA) 12:30 PM-12:40 PM SAT6-2 The principles and practice of immuno-oncology adverse event management J. Larkin (London, UK) 12:40 PM–01:10 PM SAT6-3 Expert insights into patient management Melanoma case presentations: C. Lebbé (Paris, France) Interactive discussion moderated by: C. Hoeller (Vienna Austria) SY26 THU SYMPOSIUM Chairs: C. Blank (Amsterdam, Netherlands) P. Ascierto (Napels, Italy) 01:30 PM–01:50 PM SY26-1 Update on resistance mechanisms against targeted drugs A. Roesch (Essen, Germany) 01:50 PM–02:10 PM SY26-2 The role of epigenetic adaptations in the escape from BRAF inhibitor therapy K. Smalley (Tampa, USA) 02:10 PM–02:30 PM SY26-3 Resistance against check-point inhibitors – what are the mechanisms? P. Ascierto (Napels, Italy) 02:30 PM–02:50 PM SY26-4 Strategies to overcome drug resistance in melanoma C. Blank (Amsterdam, Netherlands) SAT How to Overcome Drug Resistance Festsaal INDEX 01:30 PM–02:50 PM Summary and close C. Hoeller (Vienna, Austria) FRI 01:10 PM–01:15 PM WED 12:15 PM–12:20 PM C. Hoeller (Vienna, Austria) SCIENTIFIC PROGRAM Zeremoniensaal POSTER 12:15 PM–01:15 PM Friday, September 2, 2016 41 Scientific Program 01:30 PM–02:50 PM SY27 SYMPOSIUM Systemic Treatment of Non-Melanoma Skin Cancer Zeremoniensaal Chairs: A. Stratigos (Athens, Greece) M. Bylaitė-Bučinskienė (Vilnius, Lithuania) 01:30 PM–01:50 PM SY27-1 Systemic drugs to prevent non-melanoma skin cancer A. Stratigos (Athens, Greece) 01:50 PM–02:10 PM SY27-2 Systemic treatment of BCC – current status and future directions R. Kunstfeld (Vienna, Austria) 02:10 PM–02:30 PM SY27-3 Systemic treatment of metastatic SCC – what’s new? J. Hofbauer (Zuerich, Switzerland) 02:30 PM–02:50 PM SY27-4 Systemic treatment of cutaneous sarcomas R. Gutzmer (Hanover, Germany) 01:30 PM–02:50 PM SY28 SYMPOSIUM Tumor Immunology T. Tueting (Bonn, Germany) G. Stingl (Vienna, Austria) 01:30 PM–01:50 PM SY28-1 How tumors escape immune surveillance T. Tueting (Bonn, Austria) 01:50 PM–02:10 PM SY28-2 Killing or control – what defines an effective tumor immune-response? W. Weninger (Sidney, Australia) 02:10 PM–02:30 PM SY28-3 The role of dendritic cells in tumor immunology G. Stingl (Vienna, Austria) 02:30 PM–02:50 PM SY28-4 Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity G. Markel (Tel Aviv, Israel) POSTER FRI Chairs: SAT Rittersaal INDEX THU WED SCIENTIFIC PROGRAM Friday, September 2, 2016 42 Scientific Program SY29 SYMPOSIUM Chairs: H. Pehamberger (Vienna, Austria) M. Binder (Vienna, Austria) 01:30 PM–01:45 PM SY29-1 How do we define value in cancer care J. Kirkwood (Pittsburgh, USA) 01:45 PM–02:00 PM SY29-2 The cost impact of modern skin cancer treatments – the European view M. Binder (Vienna, Austria) 02:00 PM–02:15 PM SY29-3 The cost impact of modern skin cancer treatments – the US view S. Agarwala (New York, USA) 02:15 PM–02:30 PM SY29-4 Solutions in the adaption to new cancer treatment paradigms C. Zielinski (Vienna, Austria) Panel discussion with audience 03:00 PM–04:00 PM COFFEE BREAK THU 02:30 PM–02:50 PM SCIENTIFIC PROGRAM What’s a Drug’s Value? Geheime Ratstube WED 01:30 PM–02:50 PM Friday, September 2, 2016 MSD VIENNA COFFEEHOUSE SYMPOSIUM Great Debates of Immuno-Oncology Therapies in Advanced Melanoma Chair: Welcome and introduction A. Hauschild (Kiel, Germany) 03:05 PM–03:20 PM SAT7-1 Clinical data update on immune checkpoint inhibitors A. Hauschild (Kiel, Germany) 03:20 PM–03:30 PM SAT7-2 Debate I: Combination immunotherapy vs single‑agent immunotherapy: does combination immunotherapy outweigh monotherapy in 1L settings? S. Agarwala (New York, USA) 03:30 PM–03:40 PM SAT7-3 Debate II: Targeted therapy vs immunotherapy: is targeted therapy the most appropriate 1L treatment choice for BRAF-mutated patients? C. Blank (Amsterdam, Netherlands) INDEX 03:00 PM–03:05 PM A. Hauschild (Kiel, Germany) SAT Zeremoniensaal FRI SAT7 POSTER 03:00 PM–04:00 PM 43 Scientific Program SAT7-4 03:50 PM–04:00 PM 04:05 PM–05:25 PM Debate III: Novel combinations: should the novel immunotherapy combination regimens be built on the 1L clinical profile established by the ipilimumab + nivolumab combination? J. Weber (New York, USA) Q&A Session and close SY30 SYMPOSIUM UV-Protection, Vitamin D and Photoaging Chairs: H. Hoenigsmann (Vienna, Austria) H. Lim (Detroit, USA) 04:05 PM–04:27 PM SY30-1 UV – the good and the bad sides S. Beissert (Leipzig, Germany) 04:27 PM–04:49 PM SY30-2 Sun protection – how does it work and does it work? H. Hoenigsmann (Vienna, Austria) WED 04:49 PM–05:11 PM SY30-3 Vitamin-D – what you always wanted to know H. Lim (Detroit, USA) THU Festsaal 05:11 PM–05:25 PM SY30-4 Laser therapy of photoaging D. Sarnoff (New York, USA) FRI SCIENTIFIC PROGRAM 03:40 PM–03:50 PM Friday, September 2, 2016 04:05 PM–05:25 PM SY31 SYMPOSIUM Melanoma Surgery: Lymph Nodes to Distant POSTER INDEX SAT Zermoniensaal Chairs: M. Ross (Houston, USA) R. Andtbacka (Salt Lake City, USA) 04:05 PM–04:25 PM SY31-1 Lymph node surgery in melanoma patients J. Gershenwald (Houston, USA) 04:25 PM–04:45 PM SY31-2 Surgery of distant metastases – when and how A. Testori (Milan, Italy) 04:45 PM–05:05 PM SY31-3 Cutaneous metastases – when to excise and when to treat R. Andtbacka (Salt Lake City, USA) 05:05 PM–05:25 PM SY31-4 How does the role of surgery in melanoma change in the current therapeutic landscape M. Ross (Houston, USA) 44 Scientific Program SY32 SYMPOSIUM Smart Sequencing or Combination Therapy – in Search for the Best Strategy Rittersaal N. Haass (Queensland, Australia) K. Smalley (Tampa, USA) 04:05 PM–04:25 PM SY32-1 Sequencing in melanoma – which options do we have? C. Blank (Amsterdam, Netherlands) 04:25 PM–04:45 PM SY32-2 How can we make the best use of kinase inhibitors in melanoma? A. Hauschild (Kiel, Germany) 04:45 PM–05:05 PM SY32-3 How can we make the best use of immunotherapy in melanoma? P. Ascierto (Napels, Italy) 05:05 PM–05:25 PM SY32-4 How can we combine new drugs with local treatment strategies R. Dummer (Zuerich, Switzerland) 04:05 PM–05:25 PM SY33 SYMPOSIUM THU WED Chairs: SY33-1 What is “orphan skin cancer” R. Loewe (Vienna, Austria) 04:20 PM–04:40 PM SY33-2 Orphan drugs for orphan skin cancer J. Becker (Essen, Germany) 04:40 PM – 05:00 PM SY33-3 Surgical therapy of cutaneous sarcomas P. Funovics (Vienna, Austria) 05:00 PM–05:15 PM SY33-4 Dermatofibrosarcoma protuberans – current guidelines P. Saiag (Paris, France) 05:15 PM–05:25 PM SY33-5 Genomic and immune heterogeneity in non‑viral merkel cell carcinoma R. Tothill (Melbourne, Australia) SAT 04:05 PM–04:20 PM INDEX R. Loewe (Vienna, Austria) P. Saiag (Paris, France) POSTER Chairs: FRI Orphan Skin Cancer – Epidemiology, Histopathology, Biology, Therapy Geheime Ratstube SCIENTIFIC PROGRAM 04:05 PM–05:25 PM Friday, September 2, 2016 45 Scientific Program 05:30 PM–06:30 PM SY34 SCIENTIFIC PROGRAM SYMPOSIUM Controversies: Sentinel Node and Completion Lymph Node Dissection – Standard of Care? Festsaal Chairs: H. Pehamberger (Vienna, Austria) J. Gershenwald (Houston, USA) 05:30 PM–06:00 PM SY34-1 Pro M. Ross (Houston, USA) 06:00 PM–06:30 PM SY34-2 Contra C. Garbe (Tuebingen, Germany) Discussion with the audience 05:30 PM–06:30 PM SY35 SYMPOSIUM Skin Cancer in Special Patient Subgroups Zeremoniensaal A. Geusau (Vienna, Austria) J. Olah (Szeged, Hungary) 05:30 PM–05:50 PM SY35-1 Epidemiology and prevention of skin cancer in immunosuppressed patients A. Geusau (Vienna, Austria) 05:50 PM–06:10 PM SY35-2 Treatment of skin cancer in immune-supressed patients – different from immunocompetent patients? C. Lebbé (Paris, France) 06:10 PM–06:30 PM SY35-3 Skin cancer in patients previously irradiated – a frequent event? A. Geller (Boston, USA) FRI THU WED Chairs: POSTER INDEX SAT Friday, September 2, 2016 46 Scientific Program SY36 SYMPOSIUM Locoregional Therapy of Melanoma Metastases Rittersaal Chairs: L. Kandolf-Sekulovic (Belgrade, Serbia) S. Agarwala (Bethlehem, USA) 05:30 PM–06:50 PM SY36-1 Therapies for patients with locoregional metastases – What are our current options? R. Dummer (Zuerich, Switzerland) 05:50 PM–06:10 PM SY36-2 Intralesional therapies – what’s around the corner? S. Agarwala (Bethlehem, USA) 06:10 PM–06:30 PM SY36-3 Intralesional and systemic therapies – Which combinations are most promising? R. Andtbacka (Salt Lake City, USA) 05:30 PM–06:30 PM SY37 SYMPOSIUM SY37-1 Breaking bad news to cancer patients – the do’s and the dont’s P. Schuetzl (Vienna, Austria) 06:00 PM–06:30 PM SY37-2 Strategies to support our patients beyond Pharmacotherapy – what everyone can do E. Lehner- Baumgartner (Vienna, Austria) 08:00 PM OT3 NETWORKING EVENING THU 05:30 PM– 06:00 PM FRI E. Lehner-Baumgartner (Vienna, Austria) INDEX SAT Chair: WED Psychodermatooncology Geheime Ratstube SCIENTIFIC PROGRAM 05:30 PM–06:30 PM Friday, September 2, 2016 POSTER Heuriger Welser 47 Immuno-Oncology 12:00 PM SY40 Predictive Biomarkers in Melanoma 10:30 AM–11:30 AM PL5 Future Targets and Combinations 11:35 AM–12:05 PM OT4 Closing Ceremony 12:05 PM–12:30 PM SY42 Brain Metastases 10:30 AM–11:30 AM SCIENTIFIC PROGRAM 11:00 AM WED 10:00 AM THU FC2 A. Steiner, H. Pehamberger 09:00 AM–10:00 AM Coffee Break 10:00 AM–10:30 AM SY41 New Methods in Early Detection of Skin Cancer 10:30 AM–11:30 AM Geheime Ratstube FRI FC3 C. Posch, C. Hoeller 09:00 AM–10:00 AM Rittersaal SAT Zeremoniensaal SY39 Current Standard of Imaging Methods for Skin Cancer Patients 08:00 AM–09:00 AM INDEX 09:00 AM Festsaal SY38 Side Effects of Systemic Skin Cancer Therapies 08:00 AM–09:00 AM POSTER 08:00 AM Saturday, September 3, 2016 Exhibiton – Hofburg Galerie Scientific Program 49 Scientific Program 08:00 AM–09:00 AM SY38 SCIENTIFIC PROGRAM WED Chairs: K. Schindler (Vienna, Austria) C. Loquai (Mainz, Germany) 08:00 AM–08:15 AM SY38-1 Side effects of systemic therapies for NMSC C. Loquai (Mainz, Germany) 08:15 AM–08:30 AM SY38-2 Side effects of targeted therapies for metastatic melanoma (BRAF/MEK) C. Lebbé (Paris, France) 08:30 AM–08:45 AM SY38-3 Side effects of immunotherapies for metastatic melanoma K. Schindler (Vienna, Austria) 08:45 AM–09:00 AM SY38-4 Discussion: How will future combinations impact side effect management? 08:00 AM–09:00 AM SY39 SYMPOSIUM Current Standard of Imaging Methods for Skin Cancer Patients Zermoniensaal THU FRI SAT INDEX SYMPOSIUM Side Effects of Systemic Skin Cancer Therapies Festsaal POSTER Saturday, September 3, 2016 Chairs: N. Schwenzer (Tuebingen, Germany) M. Mayerhoefer (Vienna, Austria) 08:00 AM–08:15 AM SY39-1 Whole-body staging of melanoma N. Schwenzer (Tuebingen, Germany) 08:15 AM–08:30 AM SY39-2 Treatment response assessment in melanoma M. Mayerhoefer (Vienna, Austria) 08:30 AM–09:00 AM SY39-3 Radiopharmaceuticals for molecular imaging of melanoma M. Mitterhauser (Vienna, Austria) W. Wadsak (Vienna, Austria) 08:00 AM–09:00 AM PW2 POSTERWALK Marmorsaal/ Antekammer 50 Non-Melanoma Skin Cancer Cutaneous Lymphoma Orphan Skin Cancer Skin Cancer in General P100 - P169 P170 - P190 P191 - P196 P197 - P205 Scientific Program FC2 FREE COMMUNICATIONS 09:12 AM–09:24 AM FC2-2 Impact of adjuvant immunotherapy on survival of patients with resected stage III melanoma diagnosed in 2003–2011 in the US S. Jang (Fairfax, VA, USA) 09:24 AM–09:36 AM FC2-3 Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors L. G. Campana (Padova, Italy) 09:36 AM–09:48 AM FC2-4 Sun protection after melanoma diagnosis improves survival C. Mueller, (Vienna, Austria) 09:48 AM–10:00 AM FC2-5 Evaluation of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomised, vehicle-controlled trial E. Stockfleth (Bochum, Germany) 09:00 AM–10:00 AM FC3 FREE COMMUNICATIONS 09:00 AM–09:12 AM FC3-1 Can Melanoma treatment be guided by a panel of predictive and prognostic MicroRNA biomarkers? M. Stark (Brisbane, Australia) 09:12 AM–09:24 AM FC3-2 Response patterns to MEK inhibition, but not NRAS mutation status predict the efficacy of combined MEK/CDK4,6 targeting in melanoma C. Posch (Vienna, Austria) 09:24 AM–09:36 AM FC3-3 Incidence, course, and management of toxicities associated with cobimetinib combined with vemurafenib in the cobrim study: an updated analysis B. Dreno (Nantes, France) 09:36 AM–09:48 AM FC3-4 Basal cell carcinoma cancer stem cells promote immune evasion G. Patel (Cardiff, UK) 51 INDEX SAT C. Posch (Vienna, Austria) C. Hoeller (Vienna, Austria) Festsaal WED Inverse association between atopy and melanoma: a case-control study V. Marasigan (Leuven, Belgium) THU FC2-1 FRI 09:00 AM–09:12 AM SCIENTIFIC PROGRAM A. Steiner (Vienna, Austria) H. Pehamberger (Vienna, Austria) Zeremoniensaal POSTER 09:00 AM–10:00 AM Saturday, September 3, 2016 Scientific Program FC3-5 10:00 AM–10:30 AM 10:30 AM–11:30 AM SY40 SYMPOSIUM Predictive Biomarkers in Melanoma Festsaal Chairs: J. Becker (Essen, Germany) C. Krepler (Philadelphia, USA) 10:30 AM–10:50 AM SY40-1 What should an ideal biomarker look like? J. Becker (Essen, Germany) 10:50 AM–11:10 AM SY40-2 Biomarkers for targeted therapies beyond B-raf status D. Schadendorf (Essen, Germany) 11:10 AM–11:30 AM SY40-3 Preclinical evaluation of biomarkers to predict therapeutic response C. Krepler (Philadelphia, USA) 10:30 AM–11:30 AM SY41 SYMPOSIUM New Methods in Early Detection of Skin Cancer G. Pellacani (Modena, Italy) P. Soyer (Brisbane, Australia) 10:30 AM–10:45 AM SY41-1 Confocal microscopy/multiphoton imaging G. Pellacani (Modena, Italy) 10:45 AM–11:00 AM SY41-2 Electric impedance spectroscopy J. Malvehy (Barcelona, Spain) 11:00 AM–11:15 AM SY41-3 Total body photography A. Halpern (New York, USA) 11:15 AM–11:30 AM SY41-4 “Apps” and telemedicine H. P. Soyer (Brisbane, Australia) SAT Chairs: INDEX Zermoniensaal POSTER FRI Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and long-term followup in 24 patients C. Jonak (Vienna, Austria) COFFEE BREAK THU WED SCIENTIFIC PROGRAM 09:48 AM–10:00 AM Saturday, September 3, 2016 52 Scientific Program SY42 SYMPOSIUM M. Preusser (Vienna, Austria) A. Berghoff (Vienna, Austria) 10:30 AM–10:45 AM SY42-1 Biology of brain metastases A. Berghoff (Vienna, Austria) 10:45 AM–11:00 AM SY42-2 The leptomeningeal microenvironment as protective sanctuary for melanoma cells I. Fedorenko (Tampa, USA) 11:00 AM–11:15 AM SY42-3 How do the new therapies influence our algorithms for brain metastases? M. Preusser (Vienna, Austria) 11:15 AM–11:30 AM SY42-4 Surgery for brain metastases from cutaneous tumors J.-C. Tonn (Munich, Germany) 11:35 AM–12:05 PM PL5 PLENARY LECTURE The future of dermatooncology C. Garbe (Tuebingen, Germany) OT4 CLOSING CEREMONY FRI PL5-1 SAT H. Pehamberger (Vienna, Austria) C. Hoeller (Vienna, Austria) C. Hoeller (Vienna, Austria) INDEX Festsaal Chairs: THU Future Targets and Combinations Festsaal 12:05 PM–12:30 PM WED Chairs: SCIENTIFIC PROGRAM Brain Metastases Rittersaal POSTER 10:30 AM–11:30 AM Saturday, September 3, 2016 53 POSTER INDEX SAT FRI THU WED SCIENTIFIC PROGRAM Scientific Program A Agarwala, Sanjiv SY29; SY36, SAT7; Chair SY36 Alcalay, Joseph SY9 Andtbacka, Robert HI SY18; SY31; SY36; Chair SY31 Arenberger, Peter SY1; Chair SY16 Argenziano, Giuseppe SY3 Ascierto, Paolo SY26; SY32; Chair SY26 B Bagot, Martine SY23 Barnhill, Raymond L SY14 Bastian, Boris PL2; SY19; SY24; Chair SY24 Becker, Juergen SY33; SY40; SAT1; Chair SY40, SAT1 Beissert, Stefan SY30 Berghoff, Anna SY42; Chair SY42 Binder, Michael SY29; Chair SY29 Blank, Christian PL3; SY26; SY32, SAT7; Chair SY26 Braathen, Lasse SY17 Busam, Klaus J. SY14 Bylaitė-Bučinskienė, Mathilda Chair SY27 C Clark, Rachel SY23; PL4 D Dreno, Brigitte SY12; FC3; Chair SY12 Dummer, Reinhard SY10, SY12; SY32; SY36, SAT5; Chair SY16 Duvic, Madeleine SY23; 54 List of Chairs and Invited Speakers F Fargnoli, Maria Concetta SY4; Chair SY4 Fedorenko, Inna SY42 Forsea, Anna Maria SY6; Chair SY6 Funovics, Philipp SY33 G Garbe, Claus SY15; SY34; PL5, SAT3; Chair PL2, SAT3 Geller, Allen SY1, SY35 Gershenwald, Jeff SY9; SY15; SY31; Chair SY34 Geskin, Larissa SY20; Chair SY23 Geusau, Alexandra SY35; Chair SY35 Gnant, Michael SY15; Chair SY15 Gogas, Helen SY22; Chair SY22 Grabbe, Stephan SY7; Chair SY7 Grob, Jean-Jaque SY8; SY22; SAT2; SAT3; Chair SY8, SAT2 Gutzmer, Ralf SY20; SY27; SAT2; Chair SY20 H Haass, Nikolas SY11; Chair SY32 Hahn, Heidi SY10; Chair SY10 Halpern, Allan SY1; SY41; Chair PL2 Handisurya, Alessandra SY13; Chair SY13 Hauschild, Axel SY8; SY32; SAT7; Chair SY8, SAT7 Hayward, Nick SY24; SY2; Chair SY2; FC1 Herlyn, Meenhard SY2; Chair SY2, FC1 Hoeller, Christoph SY6; SAT4; SAT6; Chair PL1, PL5, SY19, SAT6, FC3, OT4 Hofbauer, Guenther SY13; SY27; Chair SY13 Hofmann-Wellenhof, Rainer SY3 Hoenigsmann, Herbert SY30; Chair SY30 J Janda, Monika SY1 K Kandolf-Sekulovic, Lidia Chair SY36 Kaufmann, Roland SY9; Chair SY9 Kirkwood, John SY22; SY29; Chair PL4 Kirnbauer, Reinhard SY2 Kittler, Harald SY3; SY19; SY25; Chair SY3 Knobler, Robert SY23; Chair PL4 Krepler, Clemens SY40; Chair SY40 Kumar, Rajiv SY24 Kunstfeld, Rainer SY13; SY27; Chair SY10 Kupper, Thomas SY7 L Larkin, James SY16; PL4; SAT2, SAT5, SAT6; Chair SAT5 Lebbé, Céleste SY35; SY38; SAT1; SAT6; Chair SY21 Lehner-Baumgartner, Eva SY37; Chair SY37 Lichtenberger Beate SY2; Chair SY2 Lim, Henry SY30; Chair SY30 P Papadavid, Evangelia Chair SY23 Paulitschke, Verena SY11; Chair SY11 Pehamberger, Hubert Chair PL1, SY22, SY29, SY34, PL5, SAT4, FC2 Pellacani, Giovanni SY41; Chair SY41 Petzelbauer, Peter FC1; Chair SY14, FC1 Posch, Christian FC3; Chair FC3 SCIENTIFIC PROGRAM WED S Sahin, Ugur PL2; SY18; Chair SY18 Saiag, Philippe SY33; Chair SY33 Sarnoff, Deborah SY30 Scarisbrick, Julia SY5; Chair SY5 Schadendorf, Dirk SY8, SY12; SY40; Chair PL3 Schindler, Katja SY21; SY38; Chair SY38 Schramek, Daniel SY11; Chair SY11 Schuetzl, Philipp SY37 Schuler, Gerold SY18; Chair SY18 Schwarz, Thomas SY2 Schwenzer, Nina SY39; Chair SY39 Sekulic, Aleksandar PL1; SY10 Sibaud, Vincent SY21; Chair SY21 Smalley, Keiran SY26; Chair SY32 Sober, Arthur Joel SY14 Sotiriou, Eleni SY17 Soyer, H. Peter SY41; Chair SY41 T Testori, Alessandro SY22; SY31; Chair SY15 Thomas, Luc SY25 Tonn, Joerg-Christian SY42 Trautinger, Franz SY23 Tschachler, Erwin SY2 Tschandl, Philipp SY25; Chair SY19 Tueting, Thomas SY28; Chair SY28 THU R Radakovic, Sonja SY17; Chair SY17 Robins, Perry Chair SY1 Roesch, Alexander SY 26 Roka, Florian SY9; Chair SY9 Rosendahl, Cliff SY25; Chair SY25 Ross, Merick SY15; SY31; SY34; Chair SY31 FRI O Okamoto, Ichiro SY4; Chair SY24 Olah, Judith Chair SY35 Q Qualigno, Petro Chair SY5 Stadler, Rudolf SY23 Steiner, Andreas Chair FC2 Stengel, Fernando SY1 Stingl, Georg SY28; Chair SY28 Stockfleth, Eggert SY13; FC2 Stolz, Wilhelm SY25; Chair SY25 Stratigos, Alexander SY10; SY27; Chair SY27 Szeimies, Rolf-Markus SY17; Chair SY17 V Vermeer, Maarten SY5 W Wadsak Wolfgang SY39 Weber, Jefrey PL1; SY12; SAT6, SAT7; Chair SY12 Weninger, Wolfgang SY7; SY28; Chair SY7 Willemze, Rein SY5 Whittaker, Sean SY5 Wolff, Klaus Chair PL1 Z Zalaudek, Iris SY3; SAT3; Chair SY3 Zielinski, Christoph SY29 55 SAT M Malvehy, Josep SY3; SY41; Chair SY4 Markel, Gal SY28 Marmol, Veronique Del SY1; Chair SY1 Mayerhoefer, Marius SY39; Chair SY39 McArthur, Grant SY4; SY8; SY24; Chair PL3 Michielin, Olivier SY16; PL3; SAT4 Mihm, Martin C SY14; Chair SY14 Mitterhauser, Markus SY39 Mohr, Peter SY6; Chair SY6 Mueller, Markus FC2 Preusser, Matthias SY42; Chair SY42 Puig, Susanna SY3; SY25 INDEX Loewe, Robert SY20; SY33; Chair SY33 Loquai, Carmen SY38; Chair SY38 Lorigan, Paul SY20; Chair SY20 List of Chairs and Invited Speakers POSTER Scientific Program Scientific Program Poster Exhibition SCIENTIFIC PROGRAM Please see the scientific program on p. 32 and p. 50 for the thematic distribution of the posterwalks.. P001 Cobimetinib plus vemurafenib for unresectable or metastatic melanoma: characteristics and safety data in 376 patients from the French temporary authorization for use Dreno B.1, Zehou O.2, Meyer N.3, Mateus C.4, Duval Modeste A.‑B.5, Lebbe C.6 1 CHU de Nantes – Hotel Dieu, Department of Dermatology, Nantes, France, 2Hôpital Henri Mondor, Department of Dermatology, Créteil, France, 3IUCT – Oncopole, Department of Dermatology, Toulouse, France, 4Gustave Roussy, Department of Dermatology, Villejuif, France, 5CHU de Rouen – Hôpital Charles Nicolle, Department of Dermatology, Rouen, France, 6Hôpital Saint-Louis, Department of Oncology, Paris, France P002 Malignant melanoma in Ukraine: Figures and features Korovin S.1, Kukushkina M.1, Goulak L.2, Fedorenko Z.2, Palivets A.1, Ostafiichuk V.1, Kovalchuk P.3 National Cancer Institute, Department of Skin and Soft Tissue Tumors, Kiev, Ukraine, 2National Cancer Institute, Department of Cancer Epidemiology, Kiev, Ukraine, 3National Cancer Institute, Oncologic Orthopedy, Kiev, Ukraine 1 P003 Eleven years of melanoma patient management – observations and trends from a single‑center experience in Austria Posch C.1, Feichtenschlager V.1, Weihsengruber F.1, Rappersberger K.1 The Rudolfstiftung Hospital, Dermatology, Vienna, Austria P004 Retrospective analysis of clinical and histopathologic characteristics of Malignant Melanoma: an analysis of 24 years’ data from the Department of Dermatology in Cracow, Poland Wawrzynkiewicz M.1, Podolec K.1, Szworak M.1, Wojas‑Pelc A.1 Jagiellonian University, Collegium Medicum, Department of Dermatology, Cracow, Poland POSTER INDEX SAT FRI THU 1 P005 Ranking of risk factors for cutaneous malignant melanoma in the general population: A systematic review and meta-analysis Joosten V.H.M.J.1, Kelleners‑Smeets N.W.J.1, Dinant G.J.2, Smeets J.G.E.2, Steijlen P.M.1, Nelemans P.J.3 1 GROW Research Institute for Oncology and Developmental Biology, Dermatology, Maastricht, Netherlands, 2CAPHRI School for Public Health and Primary Care, Family medicine, Maastricht, Netherlands, 3CAPHRI School for Public Health and Primary Care, Epidemiology, Maastricht, Netherlands P006 Influence of socioeconomic status on clinical outcomes of malignant melanoma: a cross-sectional study in 746 patients Molgó M.1, Andino R.1, Navajas L.1, Silva M.J.2, Uribe P.1, Sazunic I.3, González S.2 Pontificia Universidad Católica de Chile, Dermatology, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, Chile, 3Universidad de Chile, Santiago, Chile 1 P007 Clinicopathological characteristics, treatment patterns and outcome of cutaneous melanoma in South‑East Europe: first results from the national registry of Serbian Melanoma Group Kandolf Sekulovic L.1, Babovic N.2, Nikolin B.3, Vrbic S.4, Vukanovic T.1, Ostojic N.5, Mijuskovic Z.1, Dinic M.1, Juskic K.2, Jevric M.2, Neric D.2, Todorovic M.4, Tiodorovic D.4, Nikolic D.6, Novakovic M.5, Serbian Melanoma Group 1 Medical Faculty, Military Medical Academy, Dermatology and Venerology, Belgrade, Serbia, 2Institute of Oncology and Radiology of Serbia, Melanoma and Sarcoma unit, Belgrade, Serbia, 3Institute of oncology of Vojvodina, Melanoma Unit, Novi Sad, Serbia, 4Clinical Center of Nis, Medical Oncology, Nis, Serbia, 5Medical Faculty, Military Medical Academy, Plastic and Reconstructive Surgery, Belgrade, Serbia, 6Clinical Hospital Center ‘Bezanijska Kosa’, Surgical oncology, Belgrade, Serbia 56 MELANOMA WED 1 Scientific Program Poster Exhibition P008 A single-center study on 118 re-excisions and 136 sentinel node biopsies for malignant melanoma Asdahl K.R.1, Stolle L.B.2 MELANOMA P009 Tumor necrosis factor alpha production is icreased in vitro bearing the R151C variant of MC1R gene Córdoba‑Lanús E.1, Espinoza‑Jiménez A.1, Ramos‑Trujillo E.1, Almeida‑González D.2, Fernández‑de‑Misa R.1,3 Hospital Universitario Nstra. Sra. de Candelaria, Research Unit, Santa Cruz de Tenerife, Spain, 2Hospital Universitario Nstra. Sra. de Candelaria, Immunology Department, Santa Cruz de Tenerife, Spain, 3Hospital Universitario Nstra. Sra. de Candelaria, Dermatology Department, Santa Cruz de Tenerife, Spain 1 P010 The HDL receptor controls the metabolic phenotype of human metastatic melanoma cells Kinslechner K.1, Schörghofer D.1, Schütz B.1, Vallianou M.1, Röhrl C.2, Hengstschläger M.1, Moriggl R.3, Stangl H.2, Mikula M.1 SCIENTIFIC PROGRAM 1 Regionshospitalet Randers, Department of Abdominal Surgery, Randers, Denmark, 2Sygehus Lillebelt, Vejle, Department of Plastic Surgery, Vejle, Denmark Medical University of Vienna, Institute of Medical Genetics, Vienna, Austria, 2Medical University of Vienna, Institute of Medical Chemistry, Vienna, Austria, 3University of Veterinary Medicine and Medical University Vienna, Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria Fundiert Wissenschaftlichen Beiträge aus internationalen Fachpublikationen in deutscher Übersetzung Kompetent Auswahl und praxisrelevante Kommentierung von Peer-Review-Arbeiten durch namhaften Fachbeirat Praxisnah Übersichtlich aufbereitete Informationen für Fachärzte für Haut- & Geschlechtskrankheiten Neugierig? Bestellen Sie gleich hier ein kostenloses Probeheft: S. Karger Medical and Scientific Publishers Basel . Freiburg . Paris . London . New York . Chennai . New Delhi . Bangkok . Beijing . Shanghai . Tokyo . Kuala Lumpur . Singapore . Sydney Wissenstransfer aus Unseren Abo-Service erreichen Sie unter: t +49 761 45 207-24, f -14 aboservice@karger.com Besuchen Sie unsere Homepage: 57 www.karger.com/kkd THU FRI Wissenstransfer aus der Forschung in die Praxis SAT Medical University of Vienna, Pharmacology, Vienna, Austria 1 INDEX Pharmacological targeting of the IL-6 signalling pathway in human melanoma cells of different stages Wasinger C.1, Svoboda K.1, Hohenegger M.1 POSTER P011 WED 1 Scientific Program Poster Exhibition P012 Diverse gene expression changes under targeted inhibitor treatment of primary melanoma cell cultures Cheng P.1, Freiberger S.1, Dummer R.1, Levesque M.1 University Hospital Zurich, Dermatology, Zurich, Switzerland SCIENTIFIC PROGRAM 1 P013 Choline transporter-like proteins as a novel molecular target for the therapy of melanoma Inazu M.1,2, Yamanaka T.2 Tokyo Medical University, Institute of Medical Science, Tokyo, Japan, 2Tokyo Medical University, Department of Molecular Preventive Medicine, Tokyo, Japan 1 P014 CXCL5 alters metastatic patterns of malignant melanoma Forsthuber A.1, Lipp K.1, Gröger M.2, Loewe R.1,3 Medical University of Vienna, Skin & Endothelium Research Division SERD, Department of Dermatology, Vienna, Austria, Medical University of Vienna, Core Facility Imaging, Vienna, Austria, 3Medical University of Vienna, Division of General Dermatology and Dermatooncology, Department of Dermatology, Vienna, Austria 1 2 P016 RRE inhibit melanogenesis in B16F0 melanoma cells through MAP kinase pathway Chien T.‑Y.1, Wang H.‑W.1, Liao H.‑F.1, Lin I.‑H.1, Lo Y.‑F.1, Chiang H.‑M.1, Wen K.‑C.1, Takashi Y.2 China Medical University, Cosmeceutics, Taichung, Taiwan, Republic of China, 2National University Corporation Kitami Institute of Technology, Hokkaido, Japan 1 FRI 1 University of Sydney, Discipline of Anatomy and Histology, Bosch Institute, School of Medical Sciences, Sydney Medical School, Sydney, Australia, 2Discipline of Physiology, Bosch Institute, University of Sydney, School of Medical Sciences, Sydney Medical School, Sydney, Australia P018 Cost-effectiveness of population-based skin cancer screening Hoorens I.1, Pil L.2, Vossaert K.3, Annemans L.2, Brochez L.1 POSTER INDEX SAT P017 PTEN: a novel target for vitamin D in the fight against melanoma Shariev A.1, Painter N.1, Mason R.2, Dixon K.1 University Hospital Ghent, Dermatology, Ghent, Belgium, 2University Hospital Ghent, Public Health, Ghent, Belgium, Private Practice, Maldegem, Dermatology, Maldegem, Belgium 1 3 P019 Effect and mechanisms of MGE in melanoma cells Liu Y.‑J.1, Wang H.‑W.1, Chen P.‑W.1, Lu X.‑Y.1, Hsu L.‑Y.1, Takashi Y.2, Wen K.‑C.1, Chiang H.‑M.1 1 China Medical University, Department of Cosmeceutics, Taichung, Taiwan, Republic of China, 2National University Corporation Kitami Institute of Technology, Hokkaido, Japan P020 Primary cutaneous malignant melanoma: not a rarity in Asian skin Saikia U.N.1, Khullar G.2, De D.2, Handa S.2, Radotra B.D.1 Post Graduate Institute of Medical Education and Research, Histopathology, Chandigarh, India, 2Post Graduate Institute of Medical Education and Research, Dermatology, Chandigarh, India 1 58 MELANOMA 1 Sydney Melanoma Diagnostic Centre, Dermatology, Sydney, Australia, 2São Paulo University, Dermatology Department of Hospital das Clínicas, São Paulo, Brazil, 3Melanoma Institute Australia, Dermatology, Sydney, Australia, 4Melanoma Institute Australia, Statistics, Sydney, Australia THU WED P015 Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions Rocha L.1,2, Guitera P.1,3, Khoury R.1, Avramidis M.3, Lo S.4, Menzies S.1 Scientific Program Poster Exhibition P021 Evaluation of nodal cellular morphology and pigmentation as prognostic factors in melanoma patients with positive sentinel nodes Bertolli E.1, Macedo M.P.2, Molina A.S.1, Damascena A.S.3, Pinto C.A.L.2, Duprat Neto J.P.1 P022 Micromorphometric evaluation of sentinel nodes in melanoma patients: The value of metastatic size, localization, and depth Bertolli E.1, Macedo M.P.2, Molina A.S.1, Damascena A.S.3, Pinto C.A.L.2, Duprat Neto J.P.1 1 AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo, Brazil, 3AC Camargo Cancer Center, International Center for Research, São Paulo, Brazil P023 A retrospective study of the pathological prognostic indicators of small diameter melanoma Coltart H.1, Dawar B.1, Darling M.2, Moyes C.3, Gupta G.4 1 University of Glasgow, Glasgow, United Kingdom, 2Queen Elizabeth University Hospital, Dermatology, Glasgow, United Kingdom, 3Queen Elizabeth University Hospital, Pathology, Glasgow, United Kingdom, 4NHS Lanarkshire, Dermatology, Glasgow, United Kingdom SCIENTIFIC PROGRAM 1 AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo, Brazil, 3AC Camargo Cancer Center, International Center for Research, São Paulo, Brazil P024 Spitz tumors and other histopathological pitfalls: Diagnosis with Dermato fluoroscopy Giering H.‑G.1, Buder S.2, Stankovic G.1, Leupold D.1 Magnosco GmbH, Berlin, Germany, 2Vivantes-Klinikum Berlin Region Süd, Berlin, Germany WED P025 Histological features of metastatic melanoma under targeted therapies - A report of 3 cases Goldman-Lévy G.1,3, Laurent-Bellue A.1, Plantier F.1, Just P.-A.1,3, Rouquette A.1, Beuvon F.1, Dallot A.1, Aractingi S.2,3, Carlotti A.1, Kramkimel N.2, Avril M.-F.2,3, Terris B.1,3 THU 1 Hôpital Cochin, Dept. of Pathology, Paris, France, 2Hôpital Cochin, Dept. of Dermatology, APHP Groupe Hospitalier Paris Centre, Paris, France, 3Université Paris Descartes, Faculty of Medecine Paris Descartes, Paris, France FRI P026 New in complex non-invasive diagnosis of melanoma Kurdina M.1, Makarenko L.2, Lebedeva A.3, Kurdina E.1 GK ‘MEDSI’, Dermatology, Moscow, Russian Federation, 2Research Center of Russian Railways, Dermatology, Moscow, Russian Federation, 3International Medical Leech Centre, Dermatology, Udelnaya pos, Russian Federation 1 SAT P028 Two-photon-excitation melanin fluorescence measurement for melanoma detection Nouri N.1, Spänkuch I.1, Lomberg D.1, Tampouri I.1, Forschner A.1, Garbe C.1 Eberhard Karl University, University Department of Oncology, Tübingen, Germany INDEX 1 P029 Pre-operative imaging for newly diagnosed primary melanoma: Stage 0 – stage IIC Callaghan D.1, Kakar R.2, Jang S.3, Venna S.3 1 Boston University, Dermatology, Boston, United States, 2University of Oklahoma, Dermatology, Oklahoma City, United States, 3Inova Schar Cancer Institute, Fairfax, United States POSTER MELANOMA 1 P030 Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice Soufir N.1,2, Benfodda M.1,2, Gazal S.3, Descamps V.4, Madjlessi N.5, Lebbe C.6, Basset‑Seguin N.6, Archimbaud A.6, Opletalova K.4, Vuong V.4, Nicaise‑Bergere C.7, Massart‑Manil S.7, Machuel B.8, Saiag P.9, Merrouche Y.10, Bensussan A.2, Nagore E.11, Kumar R.12, Grange F.13 1 Bichat Hospital, Genetic, Paris, France, 2Centre de recherche sur la peau, U976, Paris, France, 3Bichat Hospital, Biostatistic, Paris, France, 4Bichat Hospital, Dermatology, Paris, France, 5Private Practice, Dermatology, Paris, France, 6Saint Louis Hospital, Dermatology, Paris, France, 7Private General Practice, Reims, France, 8Private General Practice, Rilly La Montagne, France, 9Ambroise Pare Hospital, Dermatology, Boulogne Billancourt, France, 10Jean Godinot Institute, Reims, France, 11Instituto di Oncologia, Dermatology, Valencia, Spain, 12German Cancer Research Center, Division of Molecular Genetic Epidemiology, Heidelberg, Germany, 13CHU de Reims, Dermatology, Reims, France 59 Scientific Program Poster Exhibition SCIENTIFIC PROGRAM P031 MELADIAG: a panel of DNA biomarkers dedicated to melanoma diagnosis Benfodda M.1,2, Marinho E.3, Kumar R.4, Lamoril J.1, Beaudoux O.5, Reocreux M.1, Grange F.6, Dechamps L.3, Bensussan A.2, Merrouche Y.7, Soufir N.1,2 1 Bichat Hospital, Genetic, Paris, France, 2Centre de recherche sur la peau, U976, Paris, France, 3Bichat Hospital, Pathological Anatomy, Paris, France, 4German Cancer Research Center, Division of Molecular Genetic Epidemiology, Heidelberg, Germany, 5Jean Godinot Institute, Dermatology, Reims, France, 6CHU de Reims, Dermatology, Reims, France, 7 Jean Godinot Institute, Reims, France P032 Epidemiological pattern of patients with melanoma in Minsk region (Belarus) using digital dermoscopy (2013–2014) Prakoshyn A.1, Zhukavets A.2, Lud N.3 Vitebsk Regional Oncology Center, Vitebsk State Medical University, General Oncology, Vitebsk, Belarus, 2N.N. Alexandrov National Cancer Centre of Belarus, Minsk Region, Belarus, 3Vitebsk State Medical University, Vitebsk, Belarus 1 P033 Spectrophotometric method of intradermal test for pigmented skin lesions diagnosis Sokolova A.1, Malishevskaya N.2 Ural Medical Clinic, Yekaterinburg, Russian Federation, 2Ural Research Institute of Dermatology, Venerology and Immunopathology, Yekaterinburg, Russian Federation 1 P034 The deceiving faces of melanoma Rados J.1, Loncaric D.1, Bradamante M.1, Ilic I.2, Marinovic B.1 UHC Zagreb and School of Medicine, University of Zagreb, Department of Dermatovenereology, Zagreb, Croatia, UHC Zagreb and School of Medicine, University of Zagreb, Department of Pathology, Zagreb, Croatia 2 P035 Mobile teledermoscopy. A useful tool to evaluate suspicious lesions. Pilot project in Rosario, Argentina Alonso C.1, Salerni G.1, Fernandez Bussy R.1 Hospital Provincial del Centenario, Dermatology, Rosario, Argentina P036 Dermoscopic features of scalp melanoma Oganesian M.1, Smirnova I.1, Dobrovolskiy E.2, Getman A.3 1 Saint-Petersburg State University, Medical Faculty, Department of Infectious Diseases, Epidemiology and Dermatovenereology, Saint-Petersburg, Russian Federation, 2Svedlovsk Regional Dermatovenerologic Dispensary, Branch No.2, Nizhny Tagil, Russian Federation, 3Medical Center ‘Neo Clinic’, Department of Oncology, Tyumen, Russian Federation POSTER INDEX SAT FRI 1 P037 Decreasing dermoscopy score of pigmented lesions following treatment with mild immunostimulatory treatment Russu L.1, Sprincenatu C.1, Russu M.2, Russu E.3 1 Bioderm Medical Center, Bucharest, Romania, 2Bio Medica, Bucharest, Romania, 3Bioderm Laser Clinic, Bucharest, Romania P038 Future of care for patients at high risk for melanoma: from multimode, hyperspectral dermoscopy to self‑imaging with smartphone Farkas D.L.1,2, Vasefi F.1, MacKinnon N.B.1, Durkin A.J.3, Kelly K.M.3 Spectral Molecular Imaging Inc., Beverly Hills, United States, 2University of Southern California, Los Angeles, United States, 3University of California, Irvine, United States 1 P039 Small diameter melanomas – two case reports Štulhofer Buzina D.1, Čeović R.1, Bradamante M.1, Lončarić D.1, Jurakić Tončić R.1 1 University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia 60 MELANOMA THU WED 1 Scientific Program Poster Exhibition P040 Sudden eruption of multiple Meyerson naevi Jerkovic Gulin S.1, Rados J.2, Loncaric D.2, Ceovic R.2,3, Marinovic B.2,3 SCIENTIFIC PROGRAM 1 General Hospital Sibenik, Infectious Diseases and Dermatology and Venereology, Sibenik, Croatia, 2University Hospital Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 3University of Zagreb School of Medicine, Zagreb, Croatia P041 Total number of common and atypical melanocytic nevi in patients with melanoma in Turkey Sallahoglu K.1, Cengiz F.P.1, Emiroglu N.1, Erdogan Güven Z.2, Onsun N.1 Bezmialem Vakif University, Istanbul, Turkey, 2University of Kragujevac, Kragujevac, Serbia 1 P042 Nevus lipomatosus cutaneus superficialis of the scalp in association with melanocytic nevus Tsekova Traykovich N.1, Grozdev I.1, Balabanova M.1, Miteva L.1 Medical University Sofia, Dermatology and venereology, Sofia, Bulgaria 1 P043 Characteristics of Lymphangiogenesis in Melanoma Wenzina J.1, Puujalka E.1, Petzelbauer P.1 Medical University of Vienna, Skin & Endothelium Research Division (SERD), Vienna, Austria 1 THU P045 Single-center “real life experience” with pembrolizumab (PEMBRO) in advanced melanoma patients and analysis of baseline factors that correlate with outcome Jansen Y.1, Schreuer M.1, Neyns B.1 WED 1 Medical University of Vienna, Medical Genetics, Vienna, Austria, 2IMC University of Applied Sciences Krems, Department Life Sciences, Krems, Austria, 3Sciotec Diagnostic Technologies GmbH, Tulln, Austria, 4FIANOSTICS GmbH, Wr. Neustadt, Austria UZ Brussel, Oncologie, Jette, Belgium 1 FRI P046 Expression of MAGL as a tumor progression marker in malignant melanoma Baba Y.1, Tanese K.1, Mori M.1, Funakoshi T.1, Amagai M.1 Keio University School of Medicine, Department of Dermatology, Shinjuku, Japan 1 SAT P047 Genetic polymorphisms in toll like receptors genes as prognostic biomarkers in melanoma patients Supic G.1, Ostojic N.2, Kandolf Sekulovic L.3, Vukanovic T.3, Rajovic M.2, Mijuskovic Z.3, Magic Z.1 INDEX 1 Medical Faculty, Military Medical Academy, Institute for Medical Research, Belgrade, Serbia, 2Medical Faculty, Military Medical Academy, Plastic and Reconstructive Surgery, Belgrade, Serbia, 3Medical Faculty, Military Medical Academy, Dermatology and Venerology, Belgrade, Serbia POSTER MELANOMA P044 Generation of an affinity purified antibody for the detection of metastatic melanoma Schütz B.1, Koppensteiner A.2, Hundsberger H.2, Missbichler A.3,4, Mikula M.1 P048 Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib combined with vemurafenib in BRAFV600-mutant melanoma Daud A.1, Pavlick A.C.2, Ribas A.3, Gonzalez R.4, Lewis K.D.4, Hamid O.5, Gajewski T.F.6, Puzanov I.7, Hsu J.J.8, Rooney I.8, Choong N.W.8, Mcarthur G.A.9,10 1 University of California, San Francisco School of Medicine, Medicine (Hematology/Oncology), San Francisco, United States, 2New York University Medical Center, New York, United States, 3Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angles, United States, 4University of Colorado Comprehensive Cancer Center, Aurora, United States, 5The Angeles Clinic and Research Institute, Los Angeles, United States, 6The University of Chicago, Chicago, United States, 7Vanderbilt-Ingram Cancer Center, Nashville, United States, 8Genentech, Inc., South San Francisco, United States, 9Peter MacCallum Cancer Centre, East Melbourne, Australia, 10University of Melbourne, Parkville, Australia 61 Scientific Program Poster Exhibition SCIENTIFIC PROGRAM P049 Timing of onset and resolution of adverse events in patients with unresectable stage IIIB–IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM Andtbacka R.1, Kaufman H.2, Harrington K.3, Middleton M.4, Melcher A.3, Ottensmeier C.5, Safaei R.6, Downey G.7, He P.8, Collichio F.9 1 Huntsman Cancer Institute, University of Utah, Salt Lake City, United States, 2Rutgers Cancer Institute of New Jersey, New Brunswick, United States, 3The Institute of Cancer Research/The Royal Marsden Hospital NIHR Biomedical Research Centre, London, United Kingdom, 4Oxford NIHR Biomedical Research Centre, Department of Oncology, Oxford, United Kingdom, 5University of Southampton and University Hospital Southampton NHS Foundation Trust, Cancer Sciences Unit, Southampton, United Kingdom, 6Amgen (Europe) GmBH, Zug, Switzerland, 7Amgen Ltd., Cambridge, United Kingdom, 8 Amgen Inc., Thousand Oaks, United States, 9The University of North Carolina, Chapel Hill, United States P050 Impact of endoplasmic reticulum stress on melanoma malignancy Eigner K.1, Filik Y.1, Klambauer G.2, Swoboda A.3, Moriggl R.3, Stangl H.1, Mikula M.1, Röhrl C.1 1 Medical University of Vienna, Vienna, Austria, 2Johannes Kepler University, Linz, Austria, 3Ludwig Boltzmann Institute Cancer Research, Vienna, Austria P051 The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumab Urosevic‑Maiwald M.1, Goldinger S.M.1, Sommerauer M.2, Dummer R.1, Schaefer N.G.2,3 P054 Electrochemotherapy in the treatment of metastatic malignant melanoma: Results from the InspECT registry Kunte C.1,2, Letule V.2, Gehl J.3, Dahlstroem K.4, Curatolo P.5, Rotunno R.5, Muir T.6, Occhini A.7, Bertino G.7, Powell B.8, Saxinger W.9, Lechner G.9, Liew S.H.10, Pritchard Jones R.10, Rutkowski P.11, Zdzienicki M.11, Mowatt D.12, Sykes A.J.13, Orlando A.14, Mitsala G.14, Rossi C.R.15,16, Campana L.15,16, Brizio M.17, de Terlizzi F.18, Quaglino P.17, Odili J.8 Artemed Fachklinik, Department of Dermatologic Surgery and Dermatology, Munich, Germany, 2Ludwig-Maximilian University Munich, Department of Dermatology and Allergology, Munich, Germany, 3Copenhagen University Hospital Herlev, Center for Experimental Drug and Gene Electrotransfer, Department of Oncology, Herlev, Denmark, 4 Copenhagen University Hospital Herlev, Department of Plastic Surgery, Herlev, Denmark, 5University of Rome “La Sapienza”, Department of Dermatology and Plastic Surgery, Rome, Italy, 6James Cook University Hospital, Department of Reconstructive Plastic Surgery, Middlesbrough, United Kingdom, 7University of Pavia, Department of Otolaryngology Head & Neck Surgery, Pavia, Italy, 8St. Georges Hospital, Department of Plastic Surgery, London, United Kingdom, 9 Klinikum Wels-Grieskirchen, Department of Dermatology, Wels, Austria, 10Whiston Hospital, Department of Plastic Surgery, Prescot, United Kingdom, 11Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland, 12Christie Hospital, NHS Foundation Trust, Plastic Surgery Department, Manchester, United Kingdom, 13Christie Hospital, NHS Foundation Trust, Department of Clinical Oncology, Manchester, United Kingdom, 14Southmead Hospital, North Bristol NHS Trust, Department of Plastic and Reconstructive Surgery, Bristol, United Kingdom, 15University of Padova, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, 16University of Padova, Department of Surgery Oncology and Gastroenterology, Padova, Italy, 17University of Torino, Department of Medical Sciences, Dermatologic Clinic, Torino, Italy, 18IGEA, Scientific & Medical Department, Carpi, Italy POSTER INDEX SAT FRI 1 P055 An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel Thurneysen S.1, Cheng P.F.1, Nagel H.W.2, Kunz M.1, Jaberg‑Bentele N.1, Naegeli M.1, Guenova‑Hötzenecker E.1, Goldinger S.1, Mangana J.1, Levesque M.P.1, Dummer R.1 University Hospital Zurich, Dermatology, Zuerich, Switzerland, 2University Hospital Zurich, Nuclear Medicine, Zuerich, Switzerland 1 62 MELANOMA THU WED 1 University Hospital Zurich, Dermatology, Zurich, Switzerland, 2University Hospital Zurich, Nuclear Medicine, Zurich, Switzerland, 3Lausanne University Hospital, Nuclear Medicine and Molecular Imaging, Lausanne, Switzerland Scientific Program Poster Exhibition P056 Sentinel lymph node biopsy for lower extremity melanoma with dual-basin uptake on lymphoscintigraphy Son J.1, Kim J.‑H.1, Hur N.1, Park I.1, Choe J.‑H.1, Kim J.S.1 P057 Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study Hauschild A.1, Chapman P.B.2, Robert C.3, Larkin J.4, Haanen J.B.5, Ribas A.6, Hogg D.7, Hamid O.8, Ascierto P.A.9, Testori A.10, Lorigan P.11, Dummer R.12, Sosman J.A.13, Flaherty K.T.14, Wongchenko M.J.15, Yan Y.15, Chang I.15, Coleman S.15, Caro I.15, Mcarthur G.A.16,17 THU WED P058 TERT promoter mutations in patients with BRAFV600-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenib Wongchenko M.J.1, Larkin J.2, Mcarthur G.A.3,4, Ribas A.5, Dréno B.6, Chapman P.B.7, Maio M.8, Garbe C.9, Robert C.10, Lu W.1, Diala I.1, Darbonne W.C.1, Chang I.1, Hsu J.J.1, Caro I.1, Rooney I.1, Ascierto P.A.11, Yan Y.1 Genentech, Inc., South San Francisco, United States, 2Royal Marsden NHS Foundation Trust, London, United Kingdom, Peter MacCallum Cancer Centre, East Melbourne, Australia, 4University of Melbourne, Melbourne, Australia, 5Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, United States, 6Nantes University, Nantes, France, 7Memorial Sloan Kettering Cancer Center, New York, United States, 8University Hospital of Siena, Siena, Italy, 9University of Tuebingen, Tuebingen, Germany, 10Institut Gustave Roussy, Villejuif, France, 11Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy 1 FRI 3 SAT P060 The Sentinel Lymph Node Biopsy in thin melanoma (Breslow ≤ 0.75mm and 0.76–1.0mm) Kechagias G.1, Marra A.1, Karonidis A.1, Kyriopoulos E.1, Tsoutsos D.1 General Hospital ‘G. Gennimatas’, Plastic Surgery, Athens, Greece INDEX 1 P061 Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland Mangana J.1, Amann V.C.1, Goldinger S.M.1, Kaufmann C.2, Frauchiger A.L.1, Cheng P.1, Stögner V.3, Held U.4, Von Moos R.5, Romano E.6, Michielin O.7, Braun R.1, Levesque M.P.1, Dummer R.1 POSTER MELANOMA 1 University Hospital Schleswig-Holstein, Kiel, Germany, 2Memorial Sloan Kettering Cancer Center, New York, United States, 3Institut Gustave Roussy, Paris, France, 4Royal Marsden NHS Foundation Trust, London, United Kingdom, 5 The Netherlands Cancer Institute, Amsterdam, Netherlands, 6Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, United States, 7Princess Margaret Hospital and University Health Network, Toronto, Canada, 8The Angeles Clinic and Research Institute, Los Angeles, United States, 9Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy, 10Istituto Europeo di Oncologia, Milan, Italy, 11University of Manchester, Manchester, United Kingdom, 12University of Zurich, Zurich, Switzerland, 13Vanderbilt University School of Medicine, Nashville, United States, 14 Massachusetts General Hospital, Boston, United States, 15Genentech, Inc., South San Francisco, United States, 16Peter MacCallum Cancer Centre, East Melbourne, Australia, 17University of Melbourne, Parkville, Australia SCIENTIFIC PROGRAM 1 Samsung Medical Center,Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, Korea, Republic of University Hospital Zurich, Department of Dermatology, Zurich, Switzerland, 2University of Zurich, Zurich, Switzerland, Medical University of Vienna, Vienna, Austria, 4Horten Centre for Patient Oriented Research and Knowledge Transfer, Zurich, Switzerland, 5Cantonal Hospital Graubünden, Chur, Switzerland, 6Department of Oncology, Service of Medical Oncology, Research Unit 932, Institut Curie, Paris, France, 7University of Lausanne and Centre Hospitalier Universitaire Vaudois (CHUV), Department of Oncology, Lausanne, Switzerland 1 3 P062 Clinical and demographic characteristics of patients (pts) treated with vemurafenib in real-world setting Sadetsky N.1, Corvino F.2, Surinach A.2, Goodman G.1 Genentech, Inc., South San Francisco, United States, 2Genesis Research LLC, Hoboken, United States 1 63 Scientific Program Poster Exhibition SCIENTIFIC PROGRAM P063 Trial in progress: Clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma: CheckMate 401 Dummer R.1, Gutzmer R.2, Corrie P.3, Millward M.4, Murzhenko A.5, Maio M.6 1 UniversitätsSpital Zürich, Zurich, Switzerland, 2Medizinische Hochschule Hannover, Hannover, Germany, 3Addenbrooke’s Hospital, Cambridge, United Kingdom, 4Sir Charles Gairdner Hospital, Nedlands, Australia, 5Bristol-Myers Squibb, Princeton, United States, 6University Hospital of Siena, Siena, Italy P064 Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: A phase I, open-label, single-arm study Schadendorf D.1, Michielin O.2,3, Nägeli M.4, Goldinger S.M.4, Campigotto F.5, Kriemler‑Krahn U.6, Schmid H.A.6, Pedroncelli A.M.6, Micaletto S.4, Dummer R.4 University Hospital Essen, Department of Dermatology, Essen, Germany, 2Lausanne University Hospital (CHUV), Multidisciplinary Oncology Center, Lausanne, Switzerland, 3Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland, 4University Hospital Zürich, Department of Dermatology, Zürich, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, United States, 6Novartis Pharmaceuticals AG, Basel, Switzerland 1 P065 Photodynamic therapy of dermatological melanoma using transoethosomes drug delivery system Rady M.1, Afifi N.2, Gomaa I.3, Abdel Kader M.4 Faculty of Pharmacy and Biotechnology, German University in Cairo, Pharmaceutical Technology, Cairo, Egypt, 2Faculty of Pharmacy and Biotechnology, German University in Cairo, and Faculty of Pharmacy – Cairo University, Pharmaceutical Technology, Cairo, Egypt, 3Faculty of Pharmacy and Biotechnology, German University in Cairo, Biotechnology, Cairo, Egypt, 4German University in Cairo, Cairo, Egypt 1 Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Endocrine Surgery, Seoul, Korea, Republic of, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, Korea, Republic of SAT P067 Novel insights into hyperthermia´s therapeutic effectiveness in treating malignant melanoma Mantso T.1, Vasiliadis S.2, Lampri E.3, Anestopoulos I.2, Botaitis S.4, Goussetis G.5, Chlichlia K.2, Pappa A.2, Panagiotidis M.1 Heriot Watt University, School of Life Sciences, Edinburgh, United Kingdom, 2Democritus University of Thrace, Department of Molecular Biology & Genetics, Alexandroupolis, Greece, 3University of Ioannina, Department of Pathology, Medical School, Ioannina, Greece, 4Democritus University of Thrace, Second Department of Surgery, Medical School, Alexandroupolis, Greece, 5Heriot Watt University, School of Engineering & Physical Sciences, Edinburgh, United Kingdom POSTER INDEX 1 P068 Radiation therapy in melanoma patients with poor clinical characteristics – a collaborative experience with 107 patients Posch C.1, Steffal C.2, Haider A.1, Flechl B.2,3, Kann T.2, Weihsengruber F.1, Schratter‑Sehn A.U.2 1 The Rudolfstiftung Hospital, Dermatology, Vienna, Austria, 2Kaiser- Franz-Josef Hospital, Institute for Radio-oncology, Vienna, Austria, 3Medaustron, Wr. Neustadt, Austria P069 Immunotherapy with human iPS-cell derived myeloid cell lines producing Type I interferons against metastatic melanoma Miyashita A.1, Fukushima S.1, Nakahara S.1, Kubo Y.1, Tokuzumi A.1, Senju S.2, Nishimura Y.2, Jinnin M.1, Ihn H.1 Kumamoto University, Dermatology and Plastic Surgery, Kumamoto, Japan, Kumamoto University, Immunogenetics, Kumamoto, Japan 1 2 64 MELANOMA P066 Complete lymph node dissection could not be beneficial in sentinel lymph node positive patients Hur N.1, Kim J.1, Son J.2 FRI THU WED 1 Scientific Program Poster Exhibition P070 Treatment of primary skin melanoma with traditional medicine methods Stroka Koka A.1, Stroka L.1 ALMS Medical Care, Tirana, Albania P071 CONVERCE: Evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanoma Lesimple T.1, Campillo‑Gimenez B.1, Leccia M.T.2, Mahmoudi A.3, Lebbe C.4, French Dermatology Society 1 Centre Eugene Marquis, Rennes, France, 2CHU de Grenoble, Grenoble, France, 3Laboratoires Roche, Boulogne Billancourt, France, 4Hôpital Saint-Louis, Paris, France P072 Early follow-up of vemurafenib+cobimetinib combination therapy in 13 melanoma patients: a Roche pre-approval access program in Hungary Gorka E.1, Czirbesz K.1, Imredi E.1, Panczel G.1, Liszkay G.1 National Institute of Oncology, Dermatooncology, Budapest, Hungary 1 SCIENTIFIC PROGRAM 1 P073 Correlation between vitiligo and clinical outcome in patient with advanced melanoma treated with nivolumab Nakamura Y.1, Asami Y.1, Tanaka R.2, Teramoto Y.1, Imamura T.1, Sato S.1, Maruyama H.2, Fujisawa Y.2, Fujimoto M.2, Yamamoto A.1 Saitama Medical University International Medical Center, Skin Oncology/Dermatology, Hidaka, Japan, University of Tsukuba, Dermatology, Tsukuba, Japan 1 THU WED P074 Follow-up atypical melanocytic lesions with Dermato fluoroscopy: Rapid malignant degeneration, stable state or repair Scholz M.1, Leupold D.2, Szyc L.2, Stankovic G.2, Pfeifer L.1, Buder S.3, Giering H.‑G.2 LTB Lasertechnik Berlin GmbH, Berlin, Germany, 2Magnosco GmbH, Berlin, Germany, 3Vivantes Klinikum Berlin Region Süd, Klinik für Dermatologie und Venerologie, Berlin, Germany 1 SAT FRI P075 Multiple primary melanomas in a 59-years-old patient with xeroderma pigmentosum, with a follow-up of 36 years Abeldaño A.1, Arias M.1, Gonzalez A.2, Cinque Z.1, Romero Costa L.1, Benedetti A.1, Maskin M.1, Rothlin A.1 Hospital Gral. de Agudos Dr. Cosme Argerich. Universidad de Buenos Aires, Buenos Aires, Argentina, Hospital Dr. Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina 1 P076 Lack of vitamin D toxicity in a longterm high dose vitamin D supplementation study for cutaneous malignant melanoma (CMM) De Smedt J.1, Van Kelst S.1, Van Eecke L.1, Vanderschueren D.2, Pauwels S.3, Billen J.3, Vandenberghe K.4, Nikkels A.5, Garmyn M.1 Catholic University Leuven, Dermatology, Leuven, Belgium, 2Catholic University Leuven, Endocrinology, Leuven, Belgium, 3Catholic University Leuven, Laboratory medicine, Leuven, Belgium, 4Catholic University Leuven, Cardiology, Leuven, Belgium, 5Centre Hospitalier Universitaire de Liège, Dermatology, Liege, Belgium 1 P077 Significance of CT scans in melanoma surveillance – 10 year retrospective, single center experience Lengyel Z.1, Pozsgai M.1, Németh K.1, Gyulai R.1 University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary 1 65 INDEX 2 POSTER MELANOMA 2 Scientific Program Poster Exhibition SCIENTIFIC PROGRAM P078 The effect of psycho-educational interventions on health outcomes in individuals at increased risk for melanoma: A systematic review of randomized controlled trials Coroiu A.1, Moran C.2, Rice D.3, Kinglsland E.4, Thombs B.5,6, Korner A.1 1 McGill University, Educational and Counselling Psychology, Montreal, Canada, 2University of Ottawa, Psychology, Ottawa, Canada, 3McGill University, Psychology, Montreal, Canada, 4McGill University, Humanities and Social Sciences Library, Montreal, Canada, 5McGill University, Psychiatry, Montreal, Canada, 6Jewish General Hospital, Montreal, Canada P079 Maligant melanoma masquerading as benign dermatoses Detrixhe A.1, Lebas E.1, Nikkels A.2 University of Liège, Dept of Dermatology, Liège, Belgium, 2CHU du Sart Tilman, Dermatology, Liège, Belgium 1 P080 Successful management of Lower eyelid melanoma Kim J.M.1, Rhie J.W.1 Seoul St. Mary’s Hospital, Plastic surgery, Seocho-gu, Korea, 1 P081 Vitiligo and tumoral melanosis: signs of metastasis in a melanoma patient Tan W.P.1, Yeo B.1, Chia H.Y.1, Cheng S.1, Heng Y.K.1, Lee J.1 National Skin Centre, Singapore, Singapore National Institute of Oncology, Department of Dermatology, Budapest, Hungary THU 1 P083 Malignant melanoma of unknown primary origin treated with negative pressure wound therapy and punch graft Kim M.S.1, Lee Y.S.1, Na C.H.1, Shin B.S.1 FRI WED P082 14 months progression free survival with Dabrafenib therapy without previous stereotactic radiotherapy in a patient with Metastatic Melanoma Imrédi E.1, Czirbesz K.1, Gorka E.1, Pánczél G.1, Lőrincz L.1, Liszkay G.1 P084 Conservative surgery for subungual in situ melanoma using Matriderm® Campagnari M.1, Carneiro H.A.2, Jafelicci A.S.2, Gomes E.E.1, Bertolli E.1, Duprat Neto J.P.1 Chosun University Medical School, Department of Dermatology, Gwang-ju, Korea, Republic of 1 POSTER INDEX SAT 1 AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil P085 Invasive malignant melanoma accompanied by leukoderma Park B.J.1, Cheon D.U.1, Oh E.H.1, Shin J.M.1, Kim E.J.1, Ko J.Y.1, Ro Y.S.1, Kim J.E.1 Hanyang University College of Medicine, Dermatology, Seoul, Korea 1 P086 Pigmented epithelioid melanocytoma – report of two cases Cozzani R.1, Ferrua C.1, Molinari N.1, Gorostidy S.2, Quildrian S.3, del Águila R.1 Instituto de Oncología Ágel H. Roffo, Dermatología, Ciudad Autonoma de Buenos Aires, Argentina, 2Instituto de Oncología Ágel H. Roffo, Patología, Ciudad Autonoma de Buenos Aires, Argentina, 3Instituto de Oncología Ágel H. Roffo, Cirugía de Partes Blandas, Ciudad Autonoma de Buenos Aires, Argentina 1 P087 Challenges in staging and surveillance of patients with Neurofibromatosis and cutaneous malignant melanoma Chew P.R.1, Toh V.V.1, Kotwal A.1 Castle Hill Hospital, Department of Plastic Surgery, Hull, United Kingdom 1 66 MELANOMA 1 Scientific Program Poster Exhibition P088 Superficial spreading melanoma detected during the examination of a cutaneous horn Russu L.1, Sprincenatu C.2, Russu M.3, Carjaliu A.A.4 Bioderm Medical Center, Dermatology, Bucharest, Romania, 2Bioderm Medical Center, Bucharest, Romania, Bio Medica, Dermatology, Bucharest, Romania, 4Colentina Clinical Hospital, Dermatology, Bucharest, Romania 1 3 SCIENTIFIC PROGRAM P089 Sporotrichoid spread of amelanotic metastatic malignant melanoma Shpadaruk V.1, Mc Kiernan M.2, Fox R.2, Faust G.1, Barbieri A.2, Woo P.N.2 University Hospitals of Leicester, Leicester, United Kingdom, 2Northampton Hospital, Northampton, United Kingdom 1 P090 Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch? Haueis S.1, Kränzlin P.1, Cheng P.F.1, Mangana J.1, Dummer R.1, Goldinger S.M.1 University Hospital of Zurich, Dermatology, Zurich, Switzerland 1 P091 Multiple primary melanomas – a single centre retrospective study Menzies S.1, Rowley S.2, Ormond P.1 St James’s Hospital, Dermatology, Dublin, Ireland, 2St James’s Hospital, Dublin, Ireland 1 THU P093 Melanoma patient support – what does your patient want? Mowbray M.1, Fraser S.2, Hancock E.2, Scorgie C.2 WED 1 Magnosco GmbH, Berlin, Germany, 2Universitätsklinik Würzburg, Zentrum für Seelische Gesundheit, Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Würzburg, Germany, 3Universität Würzburg, Pathologisches Institut, Abteilung für Neuropathology, Würzburg, Germany, 4Alexianer St. Joseph-Krankenhaus, Klinik für Neurologie, Berlin, Germany NHS Fife, Scotland, Dermatology Department, Queen Margaret Hospital, Dunfermline, United Kingdom, 2NHS Fife, Scotland, Dunfermline, United Kingdom Medscape Education, New York, United States, 2Society for Immunotherapy of Cancer, Milwaukee, United States, University of Chicago, Chicago, United States, 4New York University Medical Center, New York, United States 1 SAT P095 Cancer immunotherapies in metastatic melanoma: effectiveness of unique case-based education on clinical decision-making Repetto P.1, Herrmann T.1, Warren C.1, Kadkhoda H.1, Scorzo M.2, Wiggins L.2, Luke J.3, Weber J.4 FRI 1 INDEX 3 P096 My cancer plan: An information App for patients in a cancer diagnostics programme Holm J.1, Eldon M.1, Stolle L.B.1 Vejle Hospital, Odense University Hospital, Department of Plastic Surgery, Vejle, Denmark 1 POSTER MELANOMA P092 Increased risk of melanoma without pigmentation change. Results of Dermato fluoroscopy of Parkinsonians Leupold D.1, Stankovic G.1, Riederer P.2, Monoranu C.M.3, Müller T.4 P097 Malignant melanoma, is dominant at the ends: about a new observation acral Boudghene Stambouli O.1 Faculty of Medicine, Dermatology, Tlemcen, Algeria 1 P098 Malignant melanoma and psoriasis acrolentigineux Boudghene Stambouli O.1 Faculty of Medicine, Dermatology, Tlemcen, Algeria 1 P099 Malignant melanoma lumbar and psoriasis Boudghene Stambouli O.1 Faculty of Medicine, Dermatology, Tlemcen, Algeria 1 67 Scientific Program Poster Exhibition P100 The prevalence of actinic keratosis and basal cell carcinoma and their association with UV radiation in the elderly Latvian population Balcere A.1,2, Karls R.1 P101 Merkel cell carcinoma in Franconia: Data on disease characteristics, treatment, and survival Kirchberger M.C.1, Schuler G.1, Leonhardt U.1, Hofmann L.1, Meyer M.2, Heinzerling L.1 1 University Hospital Erlangen, Department of Dermatology, Erlangen, Germany, 2Centre for Early Cancer Detection and Cancer Registration, Bavarian Health and Food Safety Authority, Nuremberg, Germany P102 CD47 expression in non-melanoma skin cancers Abbas O.1, Kurban M.1 American University of Beirut Medical Center, Dermatology, Beirut, Lebanon 1 P103 A mutual mr21-thyroid hormone interplay regulates skin tumorigenesis and BCC formation Di Girolamo D.1, Ambrosio R.1, De Stefano M.A.1, Mancino G.1, Miro C.1, De Cicco E.1, Missero C.2, Salvatore D.1, Dentice M.1 P104 Frequent loss of function mutations in TGFβR1 and TGFβR2 implicate hair follicle bulge stem cells as a cell of origin of cutaneous squamous cell carcinoma Cammareri P.1, Rose A.2, Vincent D.1, Wang J.3, Nagano A.3, Libertini S.1, Ridgway R.1, Mchugh A.2, Pourreyon C.2, Spender L.2, Sapkota G.4, Purdie K.3, Proby C.2, Harwood C.3, Leigh I.2, Barker N.5, Karlsson S.6, Pritchard C.7, Marais R.8, Chelala C.3, South A.9, Sansom O.1, Inman G.2 1 Cancer Research UK Beatson Institute, Glasgow, United Kingdom, 2University of Dundee, Division of Cancer Research, Dundee, United Kingdom, 3Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom, 4University of Dundee, Dundee, United Kingdom, 5Institute of Medical Biology, Singapore, Singapore, 6Lund University, Lund, Sweden, 7University of Leicester, Leicester, United Kingdom, 8CRUK Manchester Institute, Manchester, United Kingdom, 9Thomas Jefferson University, Philadelphia, United States P105 Cooperation of Langerhans cells and NK cells guarding the epidermis during chemical carcinogenesis Ortner D.1, Tripp C.1, Komenda K.1, Dubrac S.1, Zelger B.1, Doppler W.2, Tymoszuk P.3, Boon L.4, Clausen B.5, Stoitzner P.1 POSTER INDEX SAT FRI THU WED 1 University of Naples Federico II, Clinical Medicine and Surgery, Naples, Italy, 2University of Naples “Federico II”, Biology, Naples, Italy Medical University Innsbruck, Department of Dermatology, Venereology & Allergology, Innsbruck, Austria, 2Medical University Innsbruck, Section for Medical Biochemistry, Innsbruck, Austria, 3Medical University Innsbruck, Department of Internal Medicine VI, Innsbruck, Austria, 4Bioceros, Utrecht, Netherlands, 5Medical Center of the Johannes GutenbergUniversity Mainz, Institute for Molecular Medicine, Mainz, Germany 1 P107 K36H protects skin from photocarcinogenesis via Bax/Bcl-2 and caspase dependent signaling pathway in human epidermal keratinocytes Lyu J.‑L.1, Chu Y.1, Lin P.1, Wu J.‑S.1, Huang Y.‑H.1, Shu W.‑G.1, Wen K.‑C.1, Chiang H.‑M.1, Kuo Y.‑H.2,3 1 China Medical University, Department of Cosmeceutics, Taichung, Taiwan, Republic of China, 2China Medical University, Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, Taichung, Taiwan, Republic of China, 3 Asia University, Department of Biotechnology, Taichung, Taiwan, Republic of China 68 NON-MELANOMA SKIN CANCER SCIENTIFIC PROGRAM 1 Riga Stradiņš University, Department of Infectology and Dermatology, Riga, Latvia, 2University of Latvia, Department of Dermatovenerology, Riga, Latvia Scientific Program Poster Exhibition P108 Minichromosome maintenance protein expression in squamous cell carcinoma Stojkovic‑Filipovic J.1, Brasanac D.2, Bosic M.2, Lekic B.3 Clinic of Dermatovenereology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, 3Clinic of Dermatovenereology, Clinical Center of Serbia, Belgrade, Serbia 1 P109 A reduction in endogenous transforming growth factor-β signalling independently predicts increased tumour depth in human cutaneous squamous cell carcinoma Rose A.1, Stephen C.2, Mitchell A.3, Rickaby W.4, Coates P.5, Proby C.6, Inman G.6 University of Dundee, Division of Cancer Research and Plastic and Reconstructive Surgery, Dundee, United Kingdom, NHS Tayside, Plastic and Reconstructive Surgery, Dundee, United Kingdom, 3NHS Tayside, Department of Dermatology, Dundee, United Kingdom, 4St.Johns Institute of Dermatology, Dermatopathology, London, United Kingdom, 5Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic, 6University of Dundee, Division of Cancer Research, Dundee, United Kingdom 1 2 P110 Mid-face location of primary basal cell carcinoma related to the aggressiveness of the cancer Mawardi P.1,2, Kalim H.2, Kalim K.2, Enggar Fitri L.2, Mudigdo A.3, Wasita B.3, Oyong O.4 SCIENTIFIC PROGRAM 2 Sebelas Maret University/Dr. Moewardi Hospital, Dermatovenereology Department, Surakarta, Indonesia, 2Brawijaya University, Faculty of Medicine, Malang, Indonesia, 3Sebelas Maret University/Dr. Moewardi Hospital, Pathology Department, Surakarta, Indonesia, 4Sebelas Maret University/Dr. Moewardi Hospital, Faculty of Medicine, Surakarta, Indonesia A Danish Cancer Center retrospective study on frozen section excisions of non-melanoma skin cancer in 2015 Holm J.1, Barnkob S.1, Kjerkegaard U.K.1, Stolle L.B.1 WED P111 Vejle Hospital, Odense University Hospital, Department of Plastic Surgery, Vejle, Denmark Skin adnexal neoplasms: a real diagnosis challenge Kelati A.1, Tahiri L.2, Harmouch T.2, Mernissi F.Z.1 1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco Malignant adnexal neoplasms: Moroccan experience Kelati A.1, Tahiri L.2, Harmouch T.2, Mernissi F.Z.1 SAT P113 FRI P112 THU 1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco 1 2 Dermoscopy of scalp BCC: variability according to clinical features and anatomic sub-site Suppa M.1, Sollena P.2, Micantonio T.3, Longo C.4, Fargnoli M.C.3, Peris K.2 INDEX P114 Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium, 2Catholic University of the Sacred Heart, Department of Dermatology, Rome, Italy, 3University of L’Aquila, Department of Dermatology, L’Aquila, Italy, 4Arcispedale S. Maria Nuova-IRCCS, Dermatology and Skin Cancer, Reggio Emilia, Italy 1 P115 Characterisation of the molecular landscape of cutaneous squamous cell carcinoma Proby C.1, Inman G.1, Wang J.2, Nagano A.2, Purdie K.3, Mladkova N.3, Lambert S.3, Gulati A.3, Sherwood V.1, Saville M.1, Chelala C.2, Harwood C.3, Leigh I.1,4, Cancer Research UK Skin Tumour Laboratory University of Dundee, Ninewells Hospital, Division of Cancer Research, College of Medicine, Dundee, United Kingdom, Barts Cancer Institute, Queen Mary University of London, Bioinformatics Unit, London, United Kingdom, 3Blizzard Institute, Queen Mary University of London, Centre for Cutaneous Research, London, United Kingdom, 4Barts Cancer Institute, Queen Mary University of London, Centre for Tumour Biology, London, United Kingdom 1 2 69 POSTER NON-MELANOMA SKIN CANCER 1 Scientific Program P116 Poster Exhibition The use of liquid-based cytology in diagnostics of basal cell carcinoma and actinic keratosis Christensen E.1, Eriksen Malone Isham S.2 SCIENTIFIC PROGRAM 1 St. Olav’s University Hospital and Norwegian University of Science and Technology (NTNU), Department of Dermatology, and Department of Cancer Research and Molecular Medicine, Trondheim, Norway, 2 St. Olavs University Hospital, Department of Medicine, Trondheim, Norway P118 miRNAs as potential players RDEB cancer development Wimmer M.1, Zauner R.1, Lettner T.1, Niklas N.2, Pröll J.2, Bauer J.W.1, Reichelt J.1, Wally V.1 1 EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria, 2Red Cross Transfusion Service for Upper Austria, Linz, Austria P119 The effects of Cxcl1 antagonist on UVB-induced skin inflammation in Xeroderma pigmentosum type A deficient mice Kunisada M.1, Hosaka C.1, Nakano E.1, Enomoto H.2, Nishigori C.1 Kobe University of Medicine, Dermatology, Kobe, Japan, 2Kobe University of Medicine, Division of Neural Differentiation and Regeneration, Department of Physiology and Cell Biology, Kobe, Japan P120 5-fluorouracil loaded liposomes targeted with cetuximab inhibit skin squamous cell carcinoma in xenograft animal model Petrilli R.1,2, Eloy J.O.1,2, Lee R.J.2, Lopez R.F.V.1 College of Pharmaceutical Sciences of Ribeirão Preto – University of Sao Paulo (USP), Ribeirao Preto, Brazil, College of Pharmacy – The Ohio State University (OSU), Columbus, United States WED 1 2 THU P121 FRI 1 Hopital Saint-Louis, Paris, France, 2Centre d’Oncodermatologie CLCC/CHU de Rennes, Rennes, France, 3Hôpital Ambroise Paré, Boulogne Billancourt, France, 4CHU de Dijon, Dijon, France, 5 CHU de Montpellier, Montpellier, France, 6Institut Gustave Roussy, Villejuif, France, 7CHU de Grenoble, Grenoble, France, 8 CHRU de Lille, Lille, France, 9Centre Oscar Lambret, Lille, France, 10Laboratoires Roche, Boulogne Billancourt, France SAT INDEX POSTER VISMONEO – a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma – patients characteristics Basset‑Seguin N.1, Dupuy A.2, Saiag P.3, Dalac‑Rat S.4, Guillot B.5, Routier E.6, Leccia M.T.7, Duhamel A.8, Mirabel X.9, Benbouta I.8, Mirakovska L.8, Meddour D.8, Dib M.8, Mahmoudi A.10, Guerreschi P.8, Mortier L.8 P122 Health-Related Quality of Life (HRQoL) analysis by skindex-16 in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in patients (pts) with multiple basal cell Carcinomas (BCCs) Dréno B.1, Hauschild A.2, Maher I.3, Zloty D.4, Labeille B.5, Grob J.‑J.6, Puig S.7, Karagiannis T.8, Gilberg F.9, Schadendorf D.10, Kunstfeld R.11, Rogers G.12 1 Nantes University, Nantes, France, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Saint Louis University Medical School, St. Louis, United States, 4University of British Columbia, Vancouver, Canada, 5University Hospital of Saint-Etienne, Saint-Etienne, France, 6Timone Hospital, Marseille, France, 7Hospital Clinic de Barcelona, Barcelona, Spain, 8 Genentech, Inc., South San Francisco, United States, 9Hoffman-La Roche, Ltd, Basel, Switzerland, 10Universitätsklinikum Essen, Essen, Germany, 11Medical University of Vienna, Vienna, Austria, 12Tufts University School of Medicine, Boston, United States 70 NON-MELANOMA SKIN CANCER 1 Scientific Program Poster Exhibition P123 Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy based on tumor aggressiveness Lear J.1, Guminski A.2, Gutzmer R.3, Migden M.4, Kudchadkar R.5, Lewis K.6, Dirix L.7, Plummer R.8, Stratigos A.9, Chang A.L.10, Trefzer U.11, Loquai C.12, Kaatz M.13, Combemale P.14, Mone M.15, Castro H.16, Yi T.15, Sellami D.15, Dummer R.17 Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Royal North Shore Hospital, St Leonards, Australia, 3Medizinische Hochschule Hannover, Hannover, Germany, 4The University of Texas MD Anderson Cancer Center, Houston, United States, 5Winship Cancer Institute of Emory University, Atlanta, United States, 6University of Colorado Cancer Center, Aurora, United States, 7Sint-Augustinus Ziekenhuis, Antwerp, Belgium, 8Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 9Andreas Syggros Hospital, University of Athens, Athens, Greece, 10Stanford University School of Medicine, Redwood City, United States, 11 Dermatologikum Berlin, Berlin, Germany, 12University Medical Center Mainz, Mainz, Germany, 13University Hospital Jena, Jena, Germany, 14Centre Leon Bérard, Lyon, France, 15Novartis Pharmaceuticals Corporation, East Hanover, United States, 16Novartis Pharma AG, Basel, Switzerland, 17UniversitätsSpital Zürich, Skin Cancer Center, University Hospital, Zürich, Switzerland SCIENTIFIC PROGRAM 1 P124 Sclerodermiform basal cell carcinoma and surgical treatment. Where is the surgery limit? Ciudad Blanco C.1, Parra Blanco V.2, Suárez Fernández R.1 Hospital General Universitario Gregorio Marañón, Dermatology, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Pathology, Madrid, Spain Utilising intraoperative frozen section in the surgical management of patients with nonmelanocytic skin cancer improve outcomes Teng T.Y.1, Chia J.C.H.2, Hing E.C.H.1, Ong W.C.1, Lim J.1, Lim T.C.1, Yap Y.L.1 WED P126 Division of Plastic, Reconstructive and Aesthetic Surgery, National University Health System, Singapore, Singapore, University of Sydney, Sydney, Australia 1 P127 THU 2 Successful use of grenz rays for DSAP: Report of 8 cases Ramelyte E.1,2, Bylaite‑Bucinskiene M.2, Dummer R.1, Imhof L.1 FRI 1 University Hospital Zurich, Dermatology, Zurich, Switzerland, 2Vilnius University, Dermatovenereology, Vilnius, Lithuania SAT P128 A versatile flap for reconstruction of partial pinna defects after tumour resection – The pre-auricular flap Jayarajan R.1, Agarwal R.1 University Hospitals of Leicester, Plastic Surgery, Leicester, United Kingdom INDEX 1 P129 Long-term follow-up of two patients with Nevoid basal cell carcinoma syndrome (NBCCS) treated with Vismodegib Van Eecke L.1, Wolter P.2, Bechter O.2, Rogiers A.2, De Smedt J.1, Garmyn M.1 POSTER NON-MELANOMA SKIN CANCER 1 UZLeuven, Dermatology, Leuven, Belgium, 2UZLeuven, Oncology, Leuven, Belgium 1 P130 Erythroplasia of Queyrat (EQ): a diagnostic and therapeutic challenge Drljevic I.1, Dajic Hrvanovic S.2 1 University of Zenica, Faculty of Health, Private Clinic for Dermatovenereology ‘Dr Drljevic’, Sarajevo, Bosnia and Herzegovina, 2Cantonal Hospital Zenica, Dermatovenereology Department, Zenica, Bosnia and Herzegovina P131 Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinoma Clover A.J.1, Salwa S.2, McKiernan J.1, Buckley C.1, Bourke M.2, Kelly E.J.1, O’Sullivan S.1, Soden D.M.2 University College Cork, Department of Plastic Surgery, Cork, Ireland, 2University College Cork, Cork Cancer Research Centre, Cork, Ireland 1 71 Scientific Program P133 European Medical Center, Moscow, Russian Federation 1 Medical University of Vienna, Vienna, Austria, 2University of British Columbia, Vancouver, Canada, 3Stanford University, La Jolla, United States, 4Hôpital Saint Louis, Paris, France, 5Innovaderm Research, Inc., Montreal, Canada, 6Aix-Marseille University, Hopital Timone APHM, Marseille, France, 7Saint Louis University Medical School, St. Louis, United States, 8 Hoffman-La Roche, Ltd, Basel, Switzerland, 9Nantes University, Nantes, France, 10Tufts University School of Medicine, Boston, United States, 11Universitätsklinikum Essen, Essen, Germany P135 Development of muscle spasm during Vismodegib treatment and the effect of treatment interruptions: exploratory analyses from the STEVIE study Kunstfeld R.1, Hauschild A.2, Basset‑Séguin N.3, Hansson J.4, Dréno B.5, Mortier L.6, Ascierto P.7, Licitra L.8, Dimier N.9, Xynos I.9, Grob J.‑J.10 Medical University of Vienna, Vienna, Austria, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Hôpital Saint Louis, Paris, France, 4Karolinska University Hospital, Solna, Stockholm, Sweden, 5Nantes University, Nantes, France, 6 University of Lille 2, Lille Regional University Hospital, Lille, France, 7Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy, 8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 9Roche Products, Ltd., Welwyn Garden City, United Kingdom, 10Aix-Marseille University, Hopital Timone APHM, Marseille, France 1 P136 A randomized split-face clinical trial of daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of actinic keratosis of the face and scalp Calzavara‑Pinton P.1, Moggio E.2, Arisi M.2, Zane C.1 University of Brescia, Brescia, Italy, 2University of Brescia, Dermatology, Brescia, Italy 1 P137 Clinical care of actinic keratoses: Documentation of number and treatment modalities in a case register project in Germany Leiter U.1, Weichenthal M.2 University of Tuebingen, Dermatology, Tuebingen, Germany, 2University of Kiel, Dermatology, Kiel, Germany 1 P138 Ingenol mebutate versus daylight methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses: an intraindividual comparative analysis Fai D.1, Mavilia L.2, Genovese G.2, Fai C.1 Daniele Romasi Hospital, Dermatology, Gagliano del Capo, Italy, 2San Raffaele, Dermatology, Milano, Italy 1 72 NON-MELANOMA SKIN CANCER P134 Analysis of patients (pts) with and without basal cell carcinoma nevus syndrome (BCCNS) in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in pts with multiple Basal Cell Carcinomas (BCCs) Kunstfeld R.1, Zloty D.2, Tang J.3, Basset‑Séguin N.4, Bissonnette R.5, Grob J.‑J.6, Maher I.7, Bergström D.8, Gilberg F.8, Dréno B.9, Rogers G.10, Schadendorf D.11 FRI THU Photodynamic therapy with methylaminolevulinate (MAL-PDT) for superficial and nodular basal cell carcinoma (BCC): clinical study Dzybova E.1, Vasilevskaya E.1, Vardanyan K.1, Potekaev N.1 1 SAT INDEX POSTER Targeting tumor metabolism in the therapy of aggressive squamous cell carcinoma in patients with epidermolysis bullosa Welponer T.1, Piñón Hofbauer J.1, Gruber C.1, Kienzl M.1, Aminzadeh‑Gohari S.2, Feichtinger R.2, Lang R.1, Bauer J.W.3, Kofler B.2, Reichelt J.1 1 EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 2Laura Bassi Centre of Expertise-THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria, 3 Department of Dermatology, Paracelsus Medical University, Salzburg, Austria WED SCIENTIFIC PROGRAM P132 Poster Exhibition Scientific Program P139 Poster Exhibition Daylight photodynamic therapy with methyl aminolevulinate cream versus diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratoses: An indirect comparison Calzavara‑Pinton P.1, Zane C.1, Pacou M.2, Szeimies R.‑M.3 University of Brescia, Department of Dermatology, Brescia, Italy, 2Amaris, Paris, France, 3Klinikum Vest GmbH Academic Teaching Hospital, Dept. of Dermatology and Allergology, Recklinghausen, Germany 1 P141 SCIENTIFIC PROGRAM P140 Adapting a UV-induced skin carcinogenesis model in immunocompetent SKH1 mice to therapeutic testing of compounds against skin cancer Christensen P.1, Høyer‑Hansen M.H.1, Skak K.1 1 LEO Pharma, Ballerup, Denmark Photodynamic therapy with methylaminolevulinate (MAL-PDT) for actinic keratosis (AK): clinical study Dzybova E.1, Vasilevskaya E.1, Potekaev N.1, Vardanyan K.1 European Medical Center, Moscow, Russian Federation 1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco 1 P143 Actinic keratosis induces angiogenesis Valero T.1, Neumüller K.2, Krall C.3, Petzelbauer P.1 Medical University Vienna, Department of Dermatology, Vienna, Austria, 2Medical University Vienna, Skin & Endothelium Research Division (SERD), Vienna, Austria, 3Medical University Vienna, Institute of Medical Statistics, Vienna, Austria WED 1 THU P144 The role of histological verification of metastases in onco-dermatology Pánczél G.1, Plótár V.2, Bőcs K.3, Liszkay G.1 National Institute of Oncology, Oncodermatology, Budapest, Hungary, 2National Institute of Oncology, Molecular Pathology, Budapest, Hungary, 3National Institute of Oncology, Diagnostic Radiology, Budapest, Hungary FRI 1 Aristotle University, First Dermatology Department, Thessaloniki, Greece 1 P146 Basal Cell Carcinoma: Smartphone app control vs. clinical control Eldon M.1, Hedelund L.1, Lorentzen H.F.1, Thormann H.2, Bjørn Stolle L.3 Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark, 2Odense University Hospital, Private Practice Dermatologist, Vejle, Denmark, 3Odense University Hospital, Department of Plastic Surgery, Odense, Denmark 1 P147 Postoperative risk factors of organ transplant recipients following dermatosurgical procedures Kröpfl L.1, Schadendorf D.2, Hillen U.2, Klode J.2 Praxis Buljanovic-Kröpfl, Dermatologie, Essen, Germany, 2Universitätsklinikum Essen, Dermatologie, Essen, Germany 1 P148 Chronic radiation dermatitis induced by radiotherapy associated with cisplatin in a case of hypopharyngeal cancer Jerkovic Gulin S.1, Chiriac A.2 General Hospital Sibenik, 1 Department of Infectious Diseases, Dermatology and Venereology, Sibenik, Croatia, Dermatology Department, Nicolina Medical Centre, Apollonia University, „P.Poni“ Research Institute of Macromolecular Chemistry, Iasi, Romania 1 2 73 INDEX SAT P145 Conventional PDT vs fractional CO2 laser-assisted-PDT with short incubation time in skin cancer prevention: a randomized intraindividual comparison study with 12-month follow-up Vrani F.1, Sotiriou E.1, Vakirlis E.1, Lazaridou E.1, Ioannides D.1 POSTER NON-MELANOMA SKIN CANCER P142 What’s new in the dermoscopy of actinic keratosis? A study of 232 cases Kelati A.1, Mernissi F.Z.1 Scientific Program Poster Exhibition P149 Basal cell carcinoma axillary: about 02 cases Boudghene Stambouli O.1 Faculty of Medicine, Dermatology, Tlemcen, Algeria SCIENTIFIC PROGRAM 1 P150 Dermal substitutes in cutaneous oncology: A single center experience Campagnari M.1, Jafelicci A.S.2, Carneiro H.A.2, Brechtbühl E.R.1, Bertolli E.1, Duprat Neto J.P.1 1 AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil P151 A rare case of basal cell carcinoma of the face associated with parotid in-transit metastasis Teng T.Y.1, Xu X.1, Nallathamby V.1, Yap Y.L.1, Lim J.1, Lim T.C.1, Ong W.C.1 Divison of Plastic, Reconstructive and Aesthetic Surgery, National University Health System, Singapore, Singapore 1 P152 Two cases of squamous cell carcinoma associated with seborrhoeic keratoses Tan W.P.1, Lim C.1, Tee S.I.1 National Skin Centre, Singapore, Singapore P153 Weekly cisplatin, epirubicin, and paclitaxel induced a durable response in two cases of metastatic extramammary Paget’s disease Hirai I.1, Funakoshi T.1 Keio University School of Medicine, Dermatology, Tokyo, Japan WED 1 P154 An unexpected diagnosis of a chronic ulcer on lower extremity Açıkgöz G.1, Küçük K.1, Kılınç M.2 Gülhane School of Military Medicine, Dermatology, Ankara, Turkey, 2Gülhane School of Military Medicine, Pathology AD, Ankara, Turkey P155 SAT INDEX POSTER Gorlin syndrome with locally advanced basal cell carcinomas treated with vismodegib Abeldaño A.1, Maskin M.1, Arias M.1, Gonzalez A.2, Benedetti A.1, Lamas C.1 Hospital Gral. de Agudos Dr. Cosme Argerich. Universidad de Buenos Aires, Buenos Aires, Argentina, Hospital Dr. Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina 1 FRI THU 1 2 P156 Primary cutaneous mucinous adenocarcinoma: sex hormone receptors a clue to the aetiology Tang H.K.C.1, Housa D.2, Patel G.K.1 Prince Philip Hospital, Dermatology, Llanelli, United Kingdom, 2Prince Philip Hospital, Pathology, Llanelli, United Kingdom 1 P157 The rate and pattern of metastasis from head & neck cutaneous squamous cell carcinoma Ainscough S.1, Brown N.2 York Teaching Hospitals, Head & Neck, York, United Kingdom, 2York Teaching Hospitals, York, United Kingdom 1 P158 Dermatofibrosarcoma protuberans: diagnosis, treatment and follow-up of a case series of 8 patients Pavlova E.1, Stanimirov P.2, Slavkova S.3, Troyanova P.1 University Hospital Tsaritsa Yoanna-ISUL, Outpatient Department, Sofia, Bulgaria, 2University Hospital Alexandrovska, Department of Maxillo Facial Surgery, Sofia, Bulgaria, 3HELIOS Vogtland-Klinikum Plauen, Department of Dermatology and Allergology, Plauen, Germany 1 P159 Overgrowth of undifferentiated pleomorphic sarcoma during vismodegib treatment of locally advanced basal cell carcinoma – a case report Mijuskovic Z.P.1, Brasanac D.2, Sijan G.3, Rajovic M.3, Kandolf‑Sekulovic L.1 Faculty of Medicine, Military Medical Academy, Clinic of Dermatology and Venereology, Belgrade, Serbia, 2Faculty of Medicine, University of Belgrade, Institute of Pathology, Belgrade, Serbia, 3Faculty of Medicine, Military Medical Academy, Clinic of Plastic Surgery and Burns, Belgrade, Serbia 1 74 NON-MELANOMA SKIN CANCER 1 Scientific Program Poster Exhibition 1 University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 2The Academy of Medical Sciences of Croatia, Zagreb, Croatia, 3University Hospital Centre Zagreb, Department of Pathology and Cytology, Zagreb, Croatia, 4Clinical Hospital ‘Sveti Duh’ Zagreb, Department of Pathology and Cytology, Zagreb, Croatia P161 Characteristic of immune status of patients with basal cell carcinoma (BCC), who live in the industrial district with the highest incidence of “non-melanoma skin cancers” (NMSC) in South Ural Pisklakova T.1, Ekimova O.2 1 South Ural State University, Department of Service and Technologies of Art Processing Materials, Chelyabinsk, Russian Federation, 2Regional Dermatology and Venereology Clinic № 3, Outpatient Department, Chelyabinsk, Russian Federation P162 Lymphomatoid papulosis type D: do not ignore this entity and not to be confused with aggressive lymphoma CD8 Boudghene Stambouli O.1 SCIENTIFIC PROGRAM P160 Expression of HER family of tyrosine kynase receptors, proliferation marker Ki67 and protein p53 in multiple and solitary cutaneous squamous cell carcinoma Ledic Drvar D.1, Lipozencic J.2, Bukvic Mokos Z.1, Ilic I.3, Knezevic F.4 Faculty of Medicine, Dermatology, Tlemcen, Algeria P163 Multiple giant warts (Buschke-Lowenstein tumor) with malignant transformation Boudghene Stambouli O.1 Faculty of Medicine, Dermatology, Tlemcen, Algeria WED 1 THU P164 Non-melanoma skin cancer operative records – introduction of a proforma for complete documentation Jayarajan R.1, Ibrahim N.1, Sayed L.1 University Hospitals of Leicester, Plastic Surgery, Leicester, United Kingdom 1 FRI P165 Keratoacanthoma-like metastasis as the presenting sign of lung carcinoma: a case report Đurinec P.1, Radoš J.1, Kostović K.1, Ilić I.2, Marinović B.1 SAT 1 University of Zagreb School of Medicine, University Hospital Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 2University of Zagreb School of Medicine, University Hospital Center Zagreb, Department of Pathology, Zagreb, Croatia P166 Pigmented Bowen’s disease – how to recognize it? A case report Rados J.1, Loncaric D.1, Zuzul K.1, Curkovic D.1, Marinovic B.1 UHC Zagreb and School of Medicine, University of Zagreb, Department of Dermatovenereology, Zagreb, Croatia P167 INDEX 1 Microcystic adnexal carcinoma in atypical site (pubic region): clinic and dermatoscopy Astorino S.1, Carelli G.2, Pasquini P.3 POSTER NON-MELANOMA SKIN CANCER 1 Unit of Dermatology and s.t.d., ‘Celio’ Military Hospital, Rome, Italy, 2Army School of Health, Rome, Italy, Histopathology Service, ‘Celio’ Military Hospital, Rome, Italy 1 3 P168 Merkel cell carcinoma of the trunk and extremities in Argentina Cozzani R.1, Daffinoti A.2, Cervelo G.2, Gerino J.2, del Aguila R.1, Chapela J.2, Quildrian S.2 1 Instituto de Oncología Ágel H. Roffo – University of Buenos Aires, Dermatology, Ciudad Autonoma de Buenos Aires, Argentina, 2Instituto de Oncología Ágel H. Roffo – University of Buenos Aires, Soft Tissue Tumors, Ciudad Autonoma de Buenos Aires, Argentina P169 Clinical behaviour of Merkel cell carcinoma- the York experience Krishnan O.1, Brown J.1, Brown N.1 York Hospital, Oral & Maxillofacial Surgery, York, United Kingdom 1 75 Scientific Program P170 Poster Exhibition Diagnostic value of plasmacytoid dendritic cells in differentiating primary follicular mucinosis (FM) from lymphoma-associated FM Abbas O.1, Kurban M.1 American University of Beirut Medical Center, Dermatology, Beirut, Lebanon SCIENTIFIC PROGRAM 1 P171 Biological properties of T-cell lymphoma (Mycosis fungoides) in correlation with the clinical picture, stage and patient outcome in Croatia – ten-year follow-up Jerkovic Gulin S.1, Ceovic R.2,3, Ilic I.4, Kostovic K.2,3, Marinovic B.2,3 1 General Hospital Sibenik, Infectious Diseases, Dermatology and Venereology, Sibenik, Croatia, 2University of Zagreb School of Medicine, Zagreb, Croatia, 3University Hospital Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 4University Hospital Center Zagreb, Department of Pathology and Cytology, Zagreb, Croatia P172 Defining the mimics and the clinico-histological diagnosis criteria for Mycosis fungoides in order to minimize misdetection Kelati A.1, Harmouch T.2, Mernissi F.Z.1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco P173 Cutaneous T cell infiltrates – Immunohistochemical and genomic issues Proca Nicula A.1, Baderca F.2,3, Solovan C.1,2 University Clinic of Dermatology and Venereology, Timisoara, Romania, 2“Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 3Emergency City Hospital, Service of Pathology, Timisoara, Romania P175 THU WED 1 Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides Wieser I.1,2, Wang C.1, Alberti‑Violetti S.1, Lyons G.3, Tran C.4, Talpur R.1, Duvic M.1 FRI 1 The University of Texas M.D. Anderson Cancer Center, Dermatology, Houston, United States, 2Paracelsus Medical University, Department of Dermatology, Salzburg, Austria, 3The University of Texas, MD Anderson Cancer Center, Department of Biostatistics, Houston, United States, 4University of North Texas Health Science Center, Texas College of Osteopathic Medicine, Fort Worth, United States SAT P176 Frequency increase, clinical features, and survival outcomes of cutaneous lymphoma in Morocco: A subgroup analysis per 10-year period Kelati A.1, Safae Z.1, Mernissi F.Z.1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco INDEX 1 P177 Frequency and risk factors for secondary malignancies in patients with mycosis fungoides Cengiz F.P.1, Emiroglu N.1, Biyik Ozkaya D.1, Gulsel Bahali A.1, Su O.1, Onsun N.1 Bezmialem Vakif University, Dermatology and Veneorology, Istanbul, Turkey POSTER 1 P178 Prognostic factors of patients with mycosis fungoides Bahalı A.G.1, Su Ö.1, Cengiz F.P.1, Emiroğlu N.1, Bıyık Özkaya D.1, Onsun N.1 Bezmialem Vakif University, Dermatology, İstanbul, Turkey 1 P179 Long-term follow-up of benign course of lymphomatoid papulosis – a case report Bartolić L.1, Jović A.2, Radoš J.2, Ilić I.3, Kostović K.2 Private Specialist of Dermatology and Venereology Practice Dr. Kedmenec Bartolić, Čakovec, Croatia, University Hospital Center Zagreb, Department of Dermatology and Venereology, School of Medicine, Zagreb, Croatia, University Hospital Center Zagreb, Department of Pathology, School of Medicine, Zagreb, Croatia 1 2 3 76 CUTANEOUS LYMPHOMA 1 Scientific Program Poster Exhibition P180 Periorbital involvement in early stage mycosis fungoides Wieser I.1,2, Bush A.E.1, Dabaja B.S.3, Duvic M.1 The University of Texas M.D. Anderson Cancer Center, Department of Dermatology, Houston, United States, 2Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 3The University of Texas M.D. Anderson Cancer Center, Department of Radiation Oncology, Houston, United States P181 Hypopigmented mycosis fungoides versus mycosis fungoides with concomitant hypopigmented lesions: same disease or different variants of mycosis fungoides? Moroccan experience Kelati A.1, Mernissi F.Z.1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco 1 P182 Folliculotropic mycosis fungoides: clinical and histopathological features in a Moroccan patient series Kelati A.1, Zinoune S.2, Mernissi F.Z.1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, Faculty of Medicine, Hospital Hassan II, Fez, Morocco 1 SCIENTIFIC PROGRAM 1 P183 An unusual case of palmoplantar eczema? Mokbel R.1, Chinthapalli S.1, Rizvi H.1, Cerio R.1, Goldsmith P.1 Royal London Hospital, London, United Kingdom 1 WED P184 Primary extramedullary plasmacytoma presenting as chronic ulcerative, whitish plaques on the oral mucosa Kim J.E.1, Han J.H.1, Woo Y.J.1, Kang H.1 St. Paul’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of 1 THU P185 Cutaneous T cell lymphoma in a patient with primary biliary cirrhosis Guler Ozden M.1, Ayyıldızt T.2, Nilgün Ş.1, Tayyar C.1 Ondokuz Mayıs University Medical Faculty, Dermatology, Samsun, Turkey, Ondokuz Mayıs University, Medical Faculty, Gastroenterology, Samsun, Turkey 1 FRI 2 P186 Cutaneous manifestations of haematologic malignancies – two case reports Schmid M.A.1,2, Rainer G.1,2, Udvardi A.1,2, Birkner T.3, Chott A.4, Klapper W.5, Volc‑Platzer B.1,2 Donauspital SMZO, Department of Dermatology, Vienna, Austria, 2Karl Landsteiner Institute for Pediatric Dermatology, Vienna, Austria, 3Donauspital SMZO, Institute of Pathology, Vienna, Austria, 4Wilhelminenspital, Institute of Pathology, Vienna, Austria, 5University-Hospital Schleswig-Holstein, Department of Pathology, Kiel, Germany INDEX SAT 1 P187 Primary cutaneous CD30+ lymphoproliferative disorders: the beast or the beauty? Kelati A.1, Mernissi F.Z.1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco 1 POSTER CUTANEOUS LYMPHOMA 2 P188 Plasmablastic lymphoma presenting in the skin: report of two clinical cases Fernandes I.1, Cabral R.2, Mota F.3, Mesquita B.4, Selores M.3, Coutinho J.5, Lima M.2 1 Hospital de Santo António, Centro Hospitalar do Porto, Dermatology; Multidisciplinary Consultation for Cutaneous Lymphomas and Mastocytosis, Porto, Portugal, 2Hospital de Santo António, Centro Hospitalar do Porto, Hematology; Multidisciplinary Consultation for Cutaneous Lymphomas and Mastocytosis, Porto, Portugal, 3Hospital de Santo António, Centro Hospitalar do Porto, Dermatology, Porto, Portugal, 4Hospital de Vila Real, Centro Hospitalar de Trás-os-Montes e Alto Douro, Hematology, Porto, Portugal, 5Hospital de Santo António, Centro Hospitalar do Porto, Hematology, Porto, Portugal 77 Scientific Program Poster Exhibition P189 Primary cutaneous lymphoma of 20 cases: CHU experience of Department of Dermatology Tlemcen (West Algeria) Boudghene Stambouli O.1, Nawel A.2 Faculty of Medicine University Aboubakr Belkaid, Dermatology, Tlemcen, Algeria, 2Faculty of Medicine University Aboubakr Belkaid, Tlemcen, Algeria SCIENTIFIC PROGRAM 1 P190 Mycosis fungoides in its pseudo leprous form of pigmented skin Boudghene Stambouli O.1, Nawel A.2 1 Faculty of Medicine, Dermatology, Tlemcen, Algeria, 2Faculty of Medicine University Aboubakr Belkaid, Dermatology, Tlemcen, Algeria P191 Immune checkpoints in Merkel cell carcinoma Wehkamp U.1, Stern S.1, Krüger S.2, Röcken C.2, Egberts F.1 University Hospital Schleswig-Holstein, Department of Dermatology, Kiel, Germany, University Hospital Schleswig-Holstein, Institute of Pathology, Kiel, Germany 1 2 P192 Evaluation of the immunogenicity of viral epitopes in a cancer immunogene therapy approach for squamous cell carcinoma in RDEB Reichl V.M.1, Kienzl M.1, Stöcklinger A.2, Tockner B.1, Reichelt J.1, Gruber C.1, Pinon‑Hofbauer J.1 P193 Nodular fasciitis: an underdiagnosed entity Ferrario D.1, Luna A.1, Molinari L.1, Rodriguez Kowalczuc M.V.1, Volonteri V.1, Galimberti G.1 Hospital Italiano, Buenos Aires, Argentina POSTER INDEX SAT FRI THU 1 P194 Solitary cutaneous metastasis of renal clear cell carcinoma on nasal tip Gómez‑Zubiaur A.1, Trasobares‑Marugán L.1, Aboín‑González S.1, Medina‑Expósito I.2, Villalobos‑León M.L.3 Príncipe de Asturias Hospital, University of Alcalá, Dermatology and Venereology Department, Alcalá de Henares, Spain, 2Príncipe de Asturias Hospital, University of Alcalá, Anatomical Pathology Department, Alcalá de Henares, Spain, 3 Príncipe de Asturias Hospital, University of Alcalá, Clinical Oncology Department, Alcalá de Henares, Spain 1 P195 Successful treatment of locally advanced Merkel cell carcinoma with somatostatin analogue‑lanreotide Lengyel Z.1, Horvath Z.1, Gyulai R.1 University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary 1 P196 Merkel cell carcinoma with pancreatic metastasis: Case report and review of literature Costa Filho E.D.P.R.1, Falcão A.C.A.1, Neotti T.2, Costa Junior W.L.3, Costa F.D.2, Bertolli E.4, Duprat Neto J.P.4 AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo, Brazil, 3AC Camargo Cancer Center, Abdominal Surgery Department, São Paulo, Brazil, 4AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil 1 78 ORPHAN SKIN CANCER WED 1 EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University, Salzburg, Austria, 2Department of Molecular Biology, University of Salzburg, Salzburg, Austria Scientific Program Poster Exhibition P197 Kaposi sarcoma: General aspect and radiotherapy Ouaz H.1, Tebra S.1, Zrafi W.1, Bouaouina N.1 University Hospital Farhat Hached, Radiation Oncology, Sousse, Tunisia P198 Test-retest reproducibility and validity of a skin cancer risk factor questionnaire Joosten V.H.M.J.1, Wouters L.1, Kelleners‑Smeets N.W.J.1, Nelemans P.J.2 GROW Research Institute for Oncology and Developmental Biology, Dermatology, Maastricht, Netherlands, CAPHRI School for Public Health and Primary Care, Epidemiology, Maastricht, Netherlands 1 2 P199 Skin cancer incidence in Latvia 2007–2014: comparison with Estonia and Lithuania Ozola E.1, Donina S.1,2 Rigas Stradins University, Riga, Latvia, 2Riga East University Hospital, Riga, Latvia P200 Sunbed use: prevalence and estimated risk of melanoma across European countries participating in the Euromelanoma prevention campaign Suppa M.1, Gandini S.2, Bulliard J.L.3, Hassane N.1, del Marmol V.1 Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium, 2European Institute of Oncology, Division of Epidemiology, Biostatistics, Milan, Italy, 3Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland 1 P201 Trends in morbidity of Kaposi´s sarcoma among solid organ transplant recipients Sorin D.1, Hodak E.1,2, Mor E.2,3, Birkenfeld S.4, Davidovici B.1 WED 1 Rabin Medical Center – Beilinson Hospital, Dermatology, Petach Tikva, Israel, 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Rabin Medical Center – Beilinson Hospital, Department of Organ Transplantation, Petach Tikva, Israel, 4Clalit Health Services, Tel Aviv, Israel THU P202 Skin cancer: what do you know about it? Moroccan study Kelati A.1, Meziane M.2, Mernissi F.Z.1 Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, Faculty of Medicine, Hospital Hassan II, Fez, Morocco 1 FRI 2 SAT P203 Development and application of in vitro keratinocyte assays incorporating viability, p38, p53 endpoints to evaluate the protection efficacy of sunscreens against UV radiation Stilla A.1, Walter N.1, Hewitt N.J.2, Kunze G.1 Galderma-Spirig Spirig Pharma AG, Egerkingen, Switzerland, 2SWS, Erzhausen, Germany 1 INDEX P204 Toxiderma drug buprenorphine (Temgesic) in a patient with lung cancer with brain metastases Boudghene Stambouli O.1 Faculty of Medicine, Dermatology, Tlemcen, Algeria 1 P205 p16 expression in seborrheic keratosis in relation to the presence of Merkel cell polyomavirus Rennspiess D.1, Hillen L.1, Speel E.‑J.1, Haugg A.2, Winnepenninckx V.1, zur Hausen A.1 POSTER SKIN CANCER IN GENERAL 1 SCIENTIFIC PROGRAM 1 Maastricht University Medical Center, Pathology, Maastricht, Netherlands, 2Maastricht University Medical Center, Department of Pathology and GROW-School for Oncology & Developmental Biology, Maastricht, Netherlands 1 79 Scientific Program Poster Exhibition Karolinska Institutet, Medicine, Stockholm, Sweden, 2Karolinska Institutet, Oncology-Pathology, Stockholm, Sweden, 3Karolinska Institutet, Microbiology, Tumor and Cell Biology (MTC), Stockholm, Sweden, 4University of Turku and Turku University Hospital, Dermatology, Turku, Finland 1 P207 Recurrent nevus vs. recurrent melanoma: Differences in epidemiology and BRAF V600Emutation status Woltsche N.1, Massone C.1, Klymiuk I.2, Guelly C.2, Zweiker D.3, Bulijan M.1, Hofmann-Wellenhof R.1, Zalaudek I.1 1 Medical University of Graz, Dermatology & Venereology, Graz, Austria, 2Medical University of Graz, Centre of Medical Research, Graz, Austria, 3Medical University of Graz, Internal Medicine, Graz, Austria P208 In vivo multiphoton tomography of skin cancer Koenig K.1 1 THU WED P210 Universität des Saarlandes, Biophotonik und Lasertechnologie, Saarbrücken, Germany Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006 Blank Ch.1, Lorigan P.2, Schachter J.3, Robert C.4 , Ribas A.5, Long G. V.6, Arance A.7, Mortier L.8, Daud A.9, Carlino M. S.10, McNeil C.11, Lotem M.12, Larkin J.13, Neyns B.14, Petrella T. M.15, Hamid O.16, Zhou H.17, Ebbinghaus S.17, Ibrahim N.17, Grob J.-J.18 Netherlands Cancer Institute, Amsterdam, Netherlands; 2University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom; 3Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel; 4 Gustave Roussy and Paris-Sud University, Villejuif, France; 5University of California, Los Angeles, Los Angeles, CA; 6 Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia; 7Hospital Clinic de Barcelona, Barcelona, Spain; 8Université Lille, Centre Hospitalier Régional Universitaire de Lille, Lille, France; 9University of California, San Francisco, San Francisco, CA; 10Westmead and Blacktown Hospitals, Melanoma Institute Australia, and the University of Sydney, Sydney, Australia; 11 Chris O’Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown, Australia; 12Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, Israel; 13Royal Marsden Hospital, London, United Kingdom; 14Universitair Ziekenhuis Brussel, Brussels, Belgium; 15Sunnybrook Health Sciences Center, Toronto, ON; 16The Angeles Clinic and Research Institute, Los Angeles, CA; 17Merck & Co., Inc., Kenilworth, NJ; 18Aix Marseille University, Hôpital de la Timone, Marseille, France POSTER INDEX SAT FRI 1 80 LATE-BREAKING SCIENTIFIC PROGRAM P206 MicroRNA-203 inversely correlates with differentiation grade and suppresses cutaneous squamous cell carcinoma growth via targeting c-myc oncogene Lohcharoenkal W.1, Harada M.2, Lovén J.3, Meisgen F.1, Xu Landén N.1, Zhang L.1, Lapins J.1, Das Mahapatra K.1, Shi H.1, Nissinen L.4, Kähäri V.-M.4, Ståhle M.1, Sonkoly E.1, Grander D.2, Arsenian-Henriksson M.3, Pivarcsi A.1 Scientific Program P211 Poster Exhibition Volume and tissue composition measurements of lymphoedema with DXA scan: A novel way of measuring lymphoedema Gjorup C.A.1, Hendel H.W.2, Christensen K.B.3, Dahlstrøm K.1, Drzewiecki K.T.4, Zerahn B.5, Hölmich L.R.1 Herlev Gentofte Hospital, University of Copenhagen, Department of Plastic Surgery, Herlev, Denmark, Herlev Gentofte Hospital, University of Copenhagen, Department of Clinical Physiology and Nuclear Medicine, PET-Center, Herlev, Denmark, 3Department of Public Health, University of Copenhagen and Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 4Department of Plastic Surgery, Breast Surgery and Burns Treatment, Copenhagen, Denmark, 5Herlev Gentofte Hospital, University of Copenhagen, Department of Clinical Physiology and Nuclear Medicine, Herlev, Denmark 1 Methyl 5-aminolevulinate photodynamic therapy in the treatment of 112 basal cell carcinomas in 84 Brazilian patients Taborda V.1 1 Improving the applicability of guidelines on nonmelanoma skin cancer in frail older adults: A multidisciplinary expert consensus and systematic review of current guidelines Lubeek S.F.K.1, Borgonjen R.J.1, Van Vugt L.J.1, Olde Rikkert M.G.2, Van de Kerkhof P.C.M.1, Gerritsen M.J.P.1 Radboud University Medical Center, Dermatology, Nijmegen, Netherlands, 2Radboud University Medical Center, Geriatrics, Nijmegen, Netherlands 1 THU Lymphoedema following sentinel lymph node biopsy and/or complete lymph node dissection: Impact on health-related quality of life Gjorup C.1, Grønvold M.2, Dahlstrøm K.1, Drzewiecki K.T.3, Christensen K.B.4, Hendel H.W.5, Hölmich L.R.1 FRI P214 Herlev Gentofte Hospital, University of Copenhagen, Department of Plastic Surgery, Herlev, Denmark, Department of Public Health, University of Copenhagen and Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 3Department of Plastic Surgery, Breast Surgery and Burns Treatment, Copenhagen, Denmark, 4Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark, 5 Department of Clinical Physiology and Nuclear Medicine, PET Center, Herlev Gentofte Hospital, University of Copenhagen, Herlev, Denmark 1 Comprehensive clinical data review of patients suffering from Mycosis fungoides with bad outcome Porkert S.1, Venz M.1, Valencak J.1, Jonak C.1 1 P216 INDEX P215 SAT 2 POSTER LATE-BREAKING P213 Centro de Dermatologia e Laser de Bauru, Photodynamic Therapy Unit, Bauru, Brazil WED P212 SCIENTIFIC PROGRAM 2 Medical University of Vienna, Department of Dermatology, Vienna, Austria Assessment of QOL, illness perception, and illness behavior in 92 patients with primary cutaneous lymphoma Porkert S.1, Lehner-Baumgartner E.2, Knobler R.1, Riedl E.1, Jonak C.1 Medical University of Vienna, Department of Dermatology, Vienna, Austria, 2Medical University of Vienna, Department of Clinical Psychology, Vienna, Austria 1 81 Scientific Program Dermoscopic and Immunohistochemical changes in acquired Melanocytic Nevi following phototherapy Abdel Hay R.1 P218 P219 THU FRI SAT INDEX POSTER Lanarkshire Centre for Dermatology, Monklands Hospital, Airdrie, United Kingdom Peripheral blood lymphocyte subsets in melanoma patients treated with ECHO-7 virus and control Ozola E.1, Sālījuma E.1, Doniņa S.1,2 1 82 Faculty of Medicine, Cairo University, Dermatology, Cairo, Egypt Clinical outcome of high-risk primary cutaneous squamous cell carcinoma three years after initial treatment at a Scottish dermatology centre Ngu S.T.1, Gupta P.1, Gupta R.1, Gupta G.1 1 WED SCIENTIFIC PROGRAM 1 Rigas Stradins University, Riga, Latvia, 2Riga East University Hospital, Riga, Latvia LATE-BREAKING P217 Poster Exhibition EADO I N D UST RI A L E XH I B ITI O N List of Exhibitors 85 Exhibition Floor Plan 84 FSA Disclosure Requirement 87 t ost recen Get the m rch a e s re on on ti a rm fo in by ent care and pati o ur h it ing w exchang rs. e n rt pa industr y Industrial Exhibition Exhibition Floor Plan INDUSTRIAL EXHIBITION The industrial exhibition takes place in the Hofburg Galerie, in the Seitengalerie and in the Oberes Platzl. Marmorsaal Geheime Ratstube r Antekamme Rittersaal Hofburg Lounge Hofburg Galerie Lift Zeremoniensaal Oberes Platzl Seitengalerie Heldenplatz Speakers Preview Room Festsaal Heldenplatz Opening Hours WED, August 31 THU, September 1 FRI, September 2 SAT, September 3 84 01:30 PM–07:00 PM 09:00 AM–05:30 PM 09:00 AM–05:30 PM 09:00 AM–12:30 PM Exhibitor 3Gen, Inc./DermLite List of Exhibitors Booth No. 7 Amgen 21 Biofrontera Pharma GmbH 11 Bristol-Myers Squibb 22 Canfield Scientific, Inc. 14 Derma Medical Systems Handels- und Entwicklungs GmbH 1 Dermo Scan GmbH 3 Elekta FotoFinder Systems GmbH Heine Optotechnik GmbH & Co. KG IGEA SpA Clinical Biophysics 10 4 23 5 Incyte Corporation 13 Integra 19 MAVIG GmbH VivaScope Systems Confocallasermicroscopy 16 MEDlight 6 Merck-Pfizer Alliance 8 Merck-Pfizer Alliance 17 Mirai Medical MSD Nevisense by SciBase 2 18 9 Novartis 20 Provectus Biopharmaceuticals, Inc. 15 Therakos 12 Vielgesundheit 24 Wisepress Medical Bookshop 25 85 INDUSTRIAL EXHIBITION Industrial Exhibition Epacadostat is an investigational, novel oral immunotherapy that inhibits indoleamine-2,3-dioxygenase 1 (IDO1) OPEN FOR ENROLLMENT NCT02752074 ENROLLING COMBINATION INVESTIGATION A phase 3 study of epacadostat and pembrolizumab Patients with unresectable or metastatic melanoma Incyte and Merck combination investigational study: ECHO-301/KEYNOTE-252 RANDOMIZATION PHASE 3 Epacadostat + Pembrolizumab CO-PRIMARY ENDPOINTS Progression-Free Survival Overall Survival Pembrolizumab This study will enroll in the following regions: North America, Central/South America, Europe, Australia, and Other Select Countries Contact us to learn if any of your patients may be eligible for participation in ECHO-301 1-855-4MEDINFO (1-855-463-3463) / MEDINFO@INCYTE.COM The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation. © 2016, Incyte Corporation. All rights reserved. INC-1172 06/16 Industrial Exhibition FSA Disclosure Requirement B:216 mm S:180 mm T:210 mm BIOPHARMACEUTICALS, INC. Advancing a New Front in the War Against Cancer Amgen €95,000 (Platinum Sponsor) Biofrontera Pharma GmbH €2,850 (Exhibition Space) Bristol-Myers Squibb €102,850 (Platinum Sponsor) Elekta €4,275 (Exhibition Space) FotoFinder Systems GmbH €2,850 (Exhibition Space) Integra €3,800 (Exhibition Space) Merck-Pfizer Alliance €67,125 (Gold Sponsor) MSD €95,000 (Platinum Sponsor) Provectus Biopharmaceuticals, Inc. €19,000 (Bronze Sponsor & Lanyards) Therakos €2,850 (Exhibition Space) INDUSTRIAL EXHIBITION According to the guidelines of the FSA Code of Conduct or other codes, we disclose the financial support of: 87 Imprint Scientific Organization Hubert Pehamberger & Christoph Hoeller Medical University Vienna Department of Dermatology Währinger Gürtel 18–20 1090 Vienna, Austria Legal Organizer & PCO MCI Deutschland GmbH MCI | Berlin Office Markgrafenstrasse 56 10117 Berlin, Germany P:+49 (0)30 204590 F: +49 (0)30 2045950 E: wccs2016@mci-group.com VAT ID number: DE 114406202, Local Court Berlin-Charlottenburg, HRB 100620B Managing Directors: Gunda Stickan, Gerrit Jessen, Andreas Laube Print Lehmann Offsetdruck GmbH Picture Credits Cover page: © TTstudio – Fotolia.com (1), © kameraauge – Fotolia.com (2) Editorial Deadline August 8, 2016 All information is supplied without liability and is subject to change. 88 STRONGER TOGETHER Combine COTELLIC with Zelboraf to achieve powerful efficacy in patients with BRAF V600(+) metastatic melanoma1 Cotellic® 20 mg film-coated tablets Qualitative and quantitative composition: Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib. Excipient with known effect: Each film-coated tablet contains 36 mg lactose monohydrate. List of excipients: Tablet core: Lactose monohydrate, Microcrystalline cellulose (E460), Croscarmellose sodium (E468), Magnesium stearate (E470b). Film coating: Polyvinyl alcohol, Titanium dioxide (E171), Macrogol 3350, Talc (E553b). Therapeutic indications: Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 “Special warnings and precautions for use” and 5.1 “Pharmacodynamic properties” of the officially published Summary of Product Characteristics). Contraindications: Hypersensitivity to the active substance or to any of the excipients. Marketing Authorisation Holder: Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom General classification of supply: Product on prescription, supply through pharmacies only. Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XE38 For special warnings and precautions for use, interactions with other medicinal products and other forms of interaction as well as information on pregnancy and lactation and on undesirable effects please refer to the officially published Summary of Product Characteristics. December 2015. 1. Larkin J, et al. N Eng J Med 2014; 371:1867-1876. For further information, please visit www.roche-cotellic.com This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to Bundesamt für Sicherheit im Gesundheitswesen, Traisengasse 5, 1200 Wien, Fax: + 43 (0) 50 555 36207, Website: http://www.basg.gv.at/ and to Roche Austria GmbH, www.roche.at. PR/COBI/1603/0003 April 2016 For patients with regionally or distantly metastatic melanoma, stage IIIB, IIIC and IVM1a* IMLYGIC® (talimogene laherparepvec) NOW APPROVED IN THE EU INJECT THE LESION. IGNITE AN IMMUNE RESPONSE. THAT’S THE PRECISION OF IMLYGIC®. *Indication IMLYGIC® is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease (see sections 4.4 and 5.1 of the Summary of Product Characteristics).1 Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation. Fachkurzinformation Imlygic 106 Plaque-bildende Einheiten (PFU)/ml Injektionslösung Imlygic 108 Plaque-bildende Einheiten (PFU)/ml Injektionslösung Qualitative und Quantitative Zusammensetzung: Jede Durchstechflasche enthält 1 ml entnehmbares Volumen Imlygic in einer nominalen Konzentration von 1 x 106 (1 Million) respektive 1 x 108 (100 Millionen) Plaque-bildenden Einheiten (PFU)/ml. Sonstige Bestandteile mit bekannter Wirkung: Jede Dosis von 4 ml enthält ungefähr 30 mg (1,3 mmol) Natrium und 80 mg Sorbitol. Liste der sonstigen Bestandteile: Dinatriumphosphat-Dihydrat, NatriumdihydrogenphosphatDihydrat, Natriumchlorid, Myo-Inositol, Sorbitol (E420), Wasser für Injektionszwecke. Anwendungsgebiete: Imlygic ist indiziert zur Behandlung von Erwachsenen mit nicht resezierbarem, lokal oder entfernt metastasiertem Melanom (Stadium IIIB, IIIC und IVM1a) ohne Knochen-, Hirn-, Lungen- oder andere viszerale Beteiligung. Gegenanzeigen: Patienten mit einer Vorgeschichte einer Überempfindlichkeit gegen Talimogen laherparepvec oder einen der sonstigen Bestandteile. • Patienten, die schwer immungeschwächt sind (z. B. Patienten mit schwerer angeborener oder erworbener zellulärer und/oder humoraler Immunschwäche). Pharmakotherapeutische Gruppe: Antineoplastische und immunmodulierende Mittel, ATC-Code: L01XX51. Inhaber der Zulassung: Amgen Europe B.V., 4817 ZK Breda, NL, Vertreter in Österreich: Amgen GmbH, 1040 Wien. Verschreibungspflicht / Apothekenpflicht: Rezept- und apothekenpflichtig. Stand der Information: Juli 2016 Weitere Angaben zu Dosierung und Dauer der Anwendung, besonderen Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit sowie zu Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation. For further information please consult the Summary of Product Characteristics (SmPC). Reference: 1. Imlygic Summary of Product Characteristics. © 2016 Amgen Inc. All rights reserved. EUHQ-P-678x-0116-122547. August 2016